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Increased production of reactive 
oxygen species (ROS) disrupts 
vascular homeostasis leading to 
the development of endothelial 
dysfunction and atherosclerosis. 
Transcription factor Nrf2 protects 
cells against ROS via regulation of 
antioxidant and cytoprotective genes. 
In this thesis, the mechanisms by 
which endogenous molecules activate 
Nrf2 in the vascular endothelium 
are described. In addition, novel 
mechanisms that inhibit the Nrf2 
activity and the role of Nrf2 as a factor 
decreasing the vascular inflammation 
are suggested.
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ABSTRACT
Endothelial dysfunction plays a significant role in the development of atherosclerosis.
Production of reactive oxygen species (ROS) is increased upon pathological conditions in
the vascular wall and leads to the endothelial dysfunction. ROS are metabolized by
antioxidant and detoxification enzymes regulated by Nuclear factor E2- Related Factor 2
(Nrf2). Nrf2 regulates gene expression via an antioxidant response element (ARE) that is
conserved in the regulatory regions of target genes. Under physiological conditions, Nrf2 is
regulated by Kelch-like ECH-associated protein 1 (Keap1), which mediates its degradation.
Upon exposure to ROS, Nrf2 translocates to the nucleus and drives target gene expression.
The aim of  this  thesis  was  to  study regulatory mechanisms by which Nrf2  is  activated in
endothelial cells. Also, the mechanism by which Nrf2 mediated expression is silenced after
induction and the potential role of Nrf2 as a negative regulator of gene expression were
studied.
 Oxidized 1-palmitoyl-2-arachidonyl-sn-glycero3-phosphocholine (oxPAPC) is
a  phospholipid  present  in  atherosclerotic  lesions.  In  this  thesis  we  show  that  oxPAPC
activates  Nrf2  and  target  gene  expression  in  human  endothelial  cells  and  murine  carotid
arteries, contributing to the anti-inflammatory effects of oxPAPC. Nrf2 activation is also
induced by nitro-oleic acid (OA-NO2) that is endogenously present in the circulation and its
production is  increased during cardiac  ischemia-reperfusion injury.  Here  it  is  also  shown
that OA-NO2 activates another protective signaling pathway, heat shock response. BTB and
CNC homology 1 (BACH1) is a repressive transcription factor that binds to the same ARE
sequence  as  Nrf2.  The  functional  ARE  was  identified  from  the  BACH1  promoter  as  it
mediates the inducible expression of the BACH1 gene in an Nrf2 dependent manner. These
findings suggest a novel negative feedback mechanism by which Nrf2 reduces its own
activity. To determine the endothelial specific target genes of Nrf2, we studied gene
expression genome-wide and found that Nrf2 over-expression leads to the down-regulation
of thioredoxin interacting protein (TXNIP), an inhibitor of thioredoxin. We also showed
that Nrf2 reduces TXNIP promoter activity and expression of both TXNIP mRNA and
protein levels.
In conclusion, Nrf2 is activated by endogenous activators leading to the
increased expression of the protective genes and inhibition of inflammatory pathway.
These results support the role of Nrf2 in the protection of the endothelium due to its
antiatherogenic features.
National Library of Medical Classification: QS 532.5.E7, QT 55.6, QU 93, QU 475, QV 312, WG 510, WG 550
Medical  Subject  Headings:  Atherosclerosis;  Basic  –Leucine  Zipper  Transcription  Factors;  Endothelium,
Vascular/pathology; Endothelial cells; Gene expression; Gene regulation; Heat Shock Response; NF-E2-
Related Factor 2; Oleic Acids; Phospholipids; Phosphatidylcholines; Reactive Oxygen Species; Regulatory
Sequences; Thioredoxin; Transcription factor
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TIIVISTELMÄ
Endoteelin toimintahäiriöllä on merkittävä rooli ateroskleroosin kehittymisessä. Endoteelin
toimintahäiriössä, kuten useissa muissa patologisissa tiloissa, hapen reaktiivisten
yhdisteiden esiintyminen lisääntyy. Hapen reaktiivisia yhdisteitä metaboloi antioksidantti-
ja detoksifikaatioentsyymit, joiden ilmentymistä säätelee Nuclear factor E2-Related Factor 2
(Nrf2). Nrf2 säätelee geenien ilmentymistä antioksidanttivaste-elementin (ARE)
välityksellä, joka on konservoitunut säätelyalue-elementti kohdegeenien säätelyalueilla.
Fysiologisissa olosuhteissa Nrf2:n hajottaa inhiboiva proteiini, Kelch-like ECH-associated
protein 1 (Keap1). Aktivoivissa olosuhteissa Nrf2 siirtyy tumaan, jossa se sitoutuu
kohdegeenien säätelyalueille lisäten kohdegeenien luentaa. Tämän väitöskirjan
tarkoituksena oli tutkia Nrf2:n aktivaatiomekanismeja verisuonen endoteelisoluissa,
selvittää Nrf2-välitteisen geenien ilmentymisen hiljentymistä aktivaation jälkeen sekä
Nrf2:n potentiaalista roolia geenien alassäätelyssä.
Hapettunut 1-palmityyli-2-arakinoni-sn-glysero-3-fosfokoliini (OxPAPC) on
ateroskleroottisissa leesioissa esiintyvä fosfolipidi. Tässä työssä osoitimme oxPAPC:n
aktivoivan Nrf2:n ja lisäävän kohdegeenien ilmentymistä ihmisen verisuonen
endoteelisoluissa ja hiiren kaulavaltimossa välittäen oxPAPC:n tulehdusta vähentäviä
vaikutuksia. Nrf2 aktivoitui myös nitratun öljyhapon vaikutuksesta, jota esiintyy
verenkierrossa ja kudoksissa sydän- ja verisuonitapahtumien yhteydessä. Osoitimme
nitratun öljyhapon aktivoivan myös lämpöshokkivasteen, joka Nrf2:n tavoin aktivoi soluja
suojaavia signalointiteitä. BTB and CNC homology 1 (BACH1) on säätelytekijä, joka
kilpailee Nrf2:n kanssa ARE-elementistä kohdegeenien säätelyalueilla. BACH1-geenin
säätelyalueelta löytyi toiminnallinen ARE-elementti, jonka välityksellä Nrf2 aktivoi
BACH1-geenin luennan. Havainnon perusteella voidaan ajatella Nrf2:n vaikuttavan
negatiivisesti omien kohdegeeniensä ilmentymiseen BACH1:n ilmentymisen lisääntymisen
kautta. Havaitsimme myös Nrf2:n vähentävän tioredoksiinia inhiboivan proteiinin (TXNIP)
ilmentymistä lähetti-RNA- ja proteiinitasoilla sekä vähentävän TXNIP:n säätelyalueen
aktiivisuutta. TXNIP estää tioredoksiinin toimintaa soluissa, mahdollistaen tulehdusta
edistävien signaaliteiden aktivoitumisen.
Yhteenvetona voidaan todeta Nrf2:n aktivoituvan verisuonen endoteelisoluissa
endogeenisesti esiintyvien aineiden vaikutuksesta johtaen soluja suojaavien geenien
ilmentymisen lisääntymiseen ja tulehdusta edistävien tapahtumien vähentymiseen. Tämä
vahvistaa käsitystä Nrf2:n roolista tulehdusta vähentävänä ja aterogeneesiä hidastavana
tekijänä verisuonen endoteelisoluissa.
Luokitus: QS 532.5.E7, QT 55.6, QU 93, QU 475, QV 312, WG 510, WG 550
Yleinen suomalainen asiasanasto: ateroskleroosi; endoteeli; geenit; geenitutkimus; hapettuminen;
happiradikaalit; rasvahapot, transkriptio; verisuonet
VIII
IX
“Me jäätiin kirjaan, virkkoi Myy,
niin käy, kun liiaks kehittyy”
-Tove Jansson-
X
XI
Acknowledgements
This study was carried out in the Department of Biotechnology and Molecular Medicine, in
the groups of Cardiovascular Signaling and Molecular Medicine, A. I. Virtanen Institute,
University of Eastern Finland during years 2005-2011.
I  am deeply grateful  to  my supervisor  Docent  Anna-Liisa  Levonen for  giving
me  the  opportunity  to  do  research  in  the  field  of  cardiovascular  signaling.  Her
encouragement  and  inspirational  attitude  have  helped  me  to  push  things  forward.  I  also
thank my other supervisor, Professor Seppo Ylä-Herttuala for giving me the opportunity to
be a part of his excellent group. I admire his extensive knowledge in molecular medicine
and enthusiasm for science.
I wish to thank the official reviewers Docent Piia Aarnisalo and Docent
Katariina Öörni for their valuable and expert comments during the final preparation of this
thesis.  I  am  grateful  to  PhD  Nick  Hayward  of  Scientific  English,  UK  for  revising  the
language of this thesis.
I am deeply grateful to Emilia Kansanen, my co-author, roommate and friend;
she always has time to help and listen. Her work and help have been irreplaceable during
the studies of this thesis, as well as her support and all discussions to do with preraring this
thesis, not forgetting her friendship outside of science. I am also thankful to co-author and
roommate Matias Inkala, it was great to start a science career with him. I also want to thank
all other members of the ALL group, Annukka Kivelä, Hanna Leinonen, Anna-Kaisa
Ruotsalainen,  and  Heidi  Laitinen  for  all  their  help  and  support.  I  am  thankful  to  my  co-
authors Suvi Kuosmanen and Merja Heinäniemi for help within the lab and with
bioinformatics.
I  owe warm thanks to all  my colleagues in SYH-group. I  have always had all
the  help  and  advice  in  the  lab  that  I  need.  I  think  this  kind  of  opportunity  to  work  with
friends will never happen again. Especially I want to thank Henna Karvinen and Mari
Merentie with whom I have shared the dilemma of dividing time between science and
medical school. I also want to thank all the technicians for their valuable help, as well as
Helena Pernu and Marja Poikolainen for their help with official and non-official secretarial
problems.
My loving thanks belong to my parents Minna and Hannu, my siblings Saila,
Annukka, Magnus and Teemu, spouses of my sisters, Timo and Mikko, and of course for
my nephews Aaron and Jaakko. I am thankful also to my “family-in-law”, Pirkko, Petri and
Lotta.  All  your  love,  support,  and  time  spent  together  is  priceless  and  totally  beyond
science, not forgeting help with Unna. Also, since I still have friends outside of science and
medical school my sincere thanks go to Sanna and Heli. I wish we could meet more often.
Finally,  I  owe my deepest thanks and love to Ari-Pekka and Unna. Unna, my
little  princess,  has  given  me  more  love  and  joy  than  I  could  ever  dream  for.  Ari-Pekka,  I
thank you for sharing my life, your patience and understanding during these years. And
since we survived last year, I think we can manage everything.
Kuopio, October 31st 2011
Henna-Kaisa Jyrkkänen
XII
This study has been supported by grants from the Finnish Cultural Foudation, Finnish
Cultural Foundation of Northern Savo, Aarne Koskelo Foundation, Aarne ja Aili  Turunen
Foundation, Finnish Foundation for Cardiovascular Research, The Finnish Medical
Foundation and Faculty of Health Sciences, University of Eastern Finland.
XIII
List of the original publications
This dissertation is based on the following original publications:
I Jyrkkänen H-K*, Kansanen E*, Inkala M, Kivelä A M, Hurttila H, Heinonen S E,
Goldsteins G, Jauhiainen S, Tiainen S, Makkonen H, Oskolkova O, Afonyushkin
T, Koistinaho J, Yamamoto M, Bochkov V N, Ylä-Herttuala S, Levonen A-L. Nrf2
regulates antioxidant gene expression evoked by oxidized phospholipids in
endothelial cells and murine arteries in vivo. Circulation research. 103:e1-e9; 2008
*equal contribution
II Kansanen E, Jyrkkänen H-K, Volger O L, Leinonen H, Kivelä A M, Häkkinen S-K,
Woodcock  S  R,  Schopfer  F  J,  Horrevoets  A  J,  Ylä-Herttuala  S,  Freeman  B  A,
Levonen A-L. Nrf2-dependent and -independent responses to nitro-fatty acids in
human endothelial cells: Identification of heat shock response as the major
pathway activated by nitro-oleic acid. The Journal of biological chemistry: 285:33233-
41; 2009
III Jyrkkänen H-K, Kuosmanen S, Heinäniemi M, Laitinen H, Kansanen E, Mella-
Aho E, Leinonen H, Ylä-Herttuala S, Levonen A-L. Novel insights into the
regulation of the antioxidant response element mediated gene expression by
electrophiles: induction of the transcriptional repressor BACH1 by NRF2.
The Biochemical journal: Epub Aug 3; 2011
IV Jyrkkänen H-K, Laitinen H, Heinäniemi M, Leinonen H, Ylä-Herttuala S,
Levonen A-L. Sulforaphane and Nrf2 over-expression Reduce Thioredoxin
Interacting Protein (TXNIP) expression in endothelial cells. Manuscript 2011
The publications were adapted with the permission of the copyright owners.
XIV
XV
Contents
1 INTRODUCTION ...................................................................................................................... 1
2 REVIEW OF THE LITERATURE ............................................................................................. 3
2.1 Oxidative stress ...................................................................................................................... 3
2.2 Role of the endothelium in atheroprotection ...................................................................... 3
2.2.1 Shear stress ..................................................................................................................... 4
2.2.2 Endothelial dysfunction in atherogenesis ................................................................... 4
2.3 Stress activated signaling pathways .................................................................................... 5
2.3.1 Keap1-Nrf2 pathway ..................................................................................................... 6
2.3.1.1Nuclear factor E2-related factor 2 ......................................................................... 6
2.3.1.2 Kelch-like ECH- associated protein 1 .................................................................. 7
2.3.1.3 Keap1 mediated Nrf2 regulation ......................................................................... 7
2.3.1.4 Nrf2 activating agents ........................................................................................... 8
2.4.1.4.1 Classic Nrf2 activating agents (SFN, tBHQ, 15d-PGJ2) ................................ 8
2.3.1.4.2 Oxidized phospholipids ................................................................................. 9
2.3.1.4.1 Nitrated lipids ................................................................................................ 11
2.3.1.4 Posttranslational modifications of Nrf2 ............................................................ 11
2.3.2 Heat shock response .................................................................................................... 12
2.4 Nrf2 mediated gene regulation .......................................................................................... 13
2.4.1 Small Maf proteins-dimerization partners of Nrf2 ................................................... 13
2.4.2 Antioxidant response element.................................................................................... 13
2.4.3 BTB and CNC homology 1-a negative regulator of ARE ......................................... 14
2.5 Vascular effects of Nrf2 and its target genes ..................................................................... 16
2.5.1. Role of Nrf2 in shear stress ........................................................................................ 16
2.5.2 Role of Nrf2 in atherogenesis ..................................................................................... 16
2.5.3 General role and vascular features of Nrf2 target genes .......................................... 17
2.5.3.1 Glutathione system ............................................................................................. 17
2.5.3.2 Heme oxygenase-1 .............................................................................................. 18
2.5.3.3 NAD(P)H: quinone oxidoreductase-1 ............................................................... 18
2.5.3.4 Thioredoxin system ............................................................................................ 19
2.5.3.4.1 Thioredoxin 1 - Thioredoxin Reductase 1 ................................................... 19
2.5.3.4.2 Thioredoxin Interacting Protein ................................................................... 19
3 AIMS OF THE STUDY ............................................................................................................ 21
4 MATERIALS AND METHODS ............................................................................................. 23
4.1 Nrf2 activating agents and cell culture (I-IV) .................................................................... 23
4.2 Cloning of plasmids (I-IV) .................................................................................................. 23
4.3 Cloning of adenoviruses (III, IV) ........................................................................................ 23
4.4 SiRNA transfections (I-IV) .................................................................................................. 23
4.5 RNA isolation and quantitative real-time PCR (I-IV) ....................................................... 23
XVI
4.6 Western blotting (I, II, IV) ................................................................................................... 24
4.7 Luciferase reporter gene assay (I-IV) ................................................................................. 25
4.8 Chromatin immunopecipitation (ChIP, I-IV) .................................................................... 25
4.9 Application of oxPAPC to the carotid arteries and immunohistochemistry (I) ............ 25
4.10 Microarray analysis (II) ..................................................................................................... 26
4.11 Electromobility shift assay (III) ........................................................................................ 26
4.12 Statistical analysis (I-IV).................................................................................................... 26
5 RESULTS................................................................................................................................... 27
5.1 OxPAPC and OA-NO2 activates Nrf2 dependent target gene expression (I-II)............. 27
5.2 Identification of critical structural characteristics of oxPAPC mediating Nrf2
activation (I) ............................................................................................................................... 29
5.3 OxPAPC induces Nrf2 target genes in vivo (I) ................................................................. 30
5.4 Nrf2 dependent and independent effects of OA-NO2 on the mRNA expression of
HUVECs (II) ............................................................................................................................... 31
5.5 BACH1 is an Nrf2 inducible gene (III) .............................................................................. 31
5.6 Nrf2 negatively regulates the expression of TXNIP (IV) ................................................. 32
6 DISCUSSION ........................................................................................................................... 35
6.1 Activation of Nrf2 by agents relevant to cardiovascular diseases .................................. 35
6.2 Regulation of novel Nrf2 target genes ............................................................................... 36
6.3 Role of Nrf2 in vascular diseases ....................................................................................... 37
7 CONCLUSIONS ...................................................................................................................... 39
8 REFERENCES ........................................................................................................................... 41
APPENDIX: ORIGINAL PUBLICATIONS I-IV
XVII
Abbreviations
AP-1 Activator protein-1
ApoB100 Apolipoprotein B100
ApoE Apolipoprotein E
ARE Antioxidant response element
ASK-1 Apoptosis signaling kinase 1
BACH1 BTB and CNC homology 1
B2M 2-microglobulin
BTB Broad complex, tramtrack
and bric a brac
bZip Basic leucine zipper domain
CBP CREB binding protein
ChIP Chromatin
immunoprecipitation
CNC Cap’n’collar
CO Carbon monoxide
COX-2 Cyclooxygenase-2
CP Cysteine-proline
CREB cAMP responsive element
binding protein 1
CRM1 Chromosome region
maintenance 1
CUL3 Cullin 3
Cys Cysteine
DBD DNA-binding domain
15d-PGJ2 15-deoxy-12,14-prostaglandin
J2
EHR Extended homology region
EMSA Electromobility shift assay
ENCODE Encyclopedia of DNA
Elements
GCL Glutamate-cysteine ligase
GCLC Glutamate-cysteine ligase
catalytic subunit
GCLM Glutamate-cysteine ligase
modifier subunit
GSH Glutathione
H2O2 Hydrogen peroxide
HEK293T Human embryonic kidney
293T cells
HO-1 Heme oxygenase-1
HSE Heat shock response element
HSF Heat shock factor
HSP Heat shock protein
HSR Heat shock response
HUVEC Human umbilical vein
endothelial cell
I/R Ischemia reperfusion injury
IVR Intervening region
JNK Jun-terminal kinase
Keap1 Kelch-like ECH-associated
protein 1
LDL Low density lipoprotein
LNO2 Nitrated linoleic acid
MARE Maf recognition element
MCP1 Monocyte chemoattractant
protein 1
miRNA Micro-RNA
mmLDL Minimally modified LDL
MOI Multiplicity of infection
Neh Nrf2-ECH homology domain
NES Nuclear export signal
NFE2L2 Nuclear factor E2- Related
Factor 2 (gene)
XVIII
NF-kB Nuclear factor of kappa light
polypeptide gene enhancer in
B-cells 1
NLS Nuclear localization signal
.NO Nitric oxide
NO2- Nitrite
NO2-FA Nitrated fatty acids
NOS Nitric oxide synthase
Nox NAD(P)H oxidase
NQO1 NAD(P)H quinone
oxidoreductase 1
Nrf2 Nuclear factor E2- Related
Factor 2 (protein)
O2.- Superoxide
OA Oleic acid
OA-NO2 Nitrated oleic acid
OH· Hydroxyl radical
ONOO- Peroxynitrite
oxLDL Oxidized LDL
oxPAPC Oxidized PAPC
oxPL Oxidized phospholipid
PAPC 1-palmitoyl-2-arachidonoyl-
sn-glycero-phosphocholine
PEIPC 1-palmitoyl-2-(5,6
epoxyisoprostanoyl)-sn-
glycero-3-phosphocholine
PERK PKR-like endoplasmic
reticulum kinase
PGPC 1-palmitoyl-2-glutaryl-sn-
glycero-3-phosphocholine
POVPC 1-palmitoyl-2-oxovaleryl-sn-
glycero-3-phosphorylcholine
POZ Poxvirus and zinc finger
PPAR Peroxisome proliferator
activated receptor
PWM Position weight matrix
RBX1 Ring box 1
RNS Reactive nitrogen species
ROS Reactive oxygen species
SFN Sulforaphane
siRNA Small interfering RNA
SNP Single nucleotide
polymorphism
SOD Superoxide dismutase
tBHQ tert-Butylhydroquinone
TNF- Tumor necrosis factor- 
TRX-1 Thioredoxin 1 (protein)
TSS Transcription start site
TXN Thioredoxin 1 (gene)
TXNIP Thioredoxin interacting
protein
TXNRD1 Thioredoxin reductase 1
UPR Unfolded protein response
UTR Untranslated region
VCAM1 Vascular cell adhesion
molecule 1
SMC Smooth muscle cell
11 Introduction
Atherosclerosis is a leading cause of morbidity and mortality in Western countries despite
progress in its prevention and treatment. The development of atherosclerosis, called
atherogenesis, is a progressive process (Libby, Ridker & Hansson 2011). At the early phase,
endothelial dysfunction plays a significant role. The endothelium functions as a barrier
between blood and the vascular wall, maintaining vascular homeostasis. The force caused
by circulating blood (shear stress) also has a remarkable role in endothelial functions and
homeostasis. In endothelial dysfunction, the normal actions of the endothelium are
disrupted and its ability to maintain its integrity is reduced, leading to the increased
expression of proatherogenic genes (Chiu, Chien 2011).
The production of reactive oxygen species (ROS) is increased during ageing
and pathological conditions in the vascular wall, which mediates many proinflammatory
and proatherogenic processes. When low density lipoprotein (LDL) is present at high
concentrations in plasma, it accumulates in the intima and is oxidized by ROS (Stocker,
Keaney 2004). ROS and secondary products of lipid peroxidation are metabolized by
antioxidant and detoxification enzymes that protect cells against the harmful effects.
Nuclear factor E2- Related Factor 2 (Nrf2) is a transcription factor that regulates the
expression  of  antioxidant  and  detoxification  enzymes  on  exposure  to  ROS  or  other
electrophiles. Nrf2 regulates gene expression via the antioxidant response element (ARE)
present in the regulatory regions of target genes. Under physiological conditions, Nrf2 is
regulated by Kelch-like associated protein 1 (Keap1) that mediates rapid proteasomal
degradation of Nrf2. In oxidative or electrophilic stress, Nrf2 escapes degradation,
translocates to the nucleus and drives target gene expression (Taguchi, Motohashi &
Yamamoto 2011).
Since  increased  ROS  production  has  an  emerging  role  in  the  disruption  of
vascular homeostasis, the factors that are capable of protection against the ROS may serve
as targets for prevention or therapy of endothelial dysfunction and atherosclerosis. Nrf2
and its target genes have been postulated to have a protective role against endothelial
dysfunction and the development of atherosclerosis (Cheng, Siow & Mann 2011). However,
the  mechanisms  by  which  Nrf2  is  activated  in  endothelial  cells  in  the  vasculature  are
largely unknown and more knowledge is needed.
This thesis describes the mechanisms by which two endogenous lipid
peroxidation products, oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine
(oxPAPC)  and  nitro-oleic  acid  (OA-NO2)  activate  Nrf2  in  endothelial  cells  and  murine
arteries. A novel negative feedback mechanism, by which Nrf2 signaling is silenced after
activation, is also suggested. BTB and CNC homology 1 (BACH1) is a repressive
transcription factor that competes with Nrf2 for binding to the same consensus sequence
(Igarashi, Sun 2006), and it is shown here that BACH1 is induced by Nrf2. Further, the role
of Nrf2 in the down-regulation of genes is clarified by demonstrating the effect of Nrf2 on
the expression of thioredoxin interacting protein (TXNIP). The suppression of the
expression of proinflammatory TXNIP supports the role of Nrf2 as an antiatherogenic
protector of the endothelium.
2
32 Review of the literature
2.1 OXIDATIVE STRESS
Oxygen is a very common molecule in living organisms. It is essential in mammalian cells
and has roles in cell respiration, metabolism, and signaling. The oxygen molecule (O2) has
two unpaired electrons in different orbitals. Those electrons can be reduced by enzymes or
reactions with redox active compounds by forming superoxide
(O2.-). O2.- is formed by the reactions of NAD(P)H oxidase (Nox) and Xantine oxidase or in
the mitochondrial electron transport chain. O2.- is a highly reactive molecule. It reacts with
other  molecules  or  is  dismutated  to  hydrogen  peroxide  (H2O2) by superoxide dismutases
(SODs). H2O2 can form a highly reactive hydroxyl radical (OH.). OH. is also generated in the
myeloperoxidase mediated reaction from hydrogen chloride and O2.-. Free radicals and
other reactive oxygen molecules; O2.-, OH.,  H2O2, and hydrogen chloride, are collectively
termed as ROS (Droge 2002).
ROS are naturally formed during physiological processes such as cell
respiration  and  during  normal  metabolic  events.  In  addition,  ROS  have  a  role  in  cell
signaling. Cells have effective enzymatic and nonenzymatic protection systems against ROS
(Droge 2002). ROS activate the expression of antioxidant and detoxification enzymes that
metabolize and detoxify ROS (Stocker, Keaney 2004). In many diseases the balance between
ROS production and disposal is disrupted leading to the accumulation of ROS, termed
oxidative stress. Oxidative stress can occur for two reasons; increased production of ROS or
defective cellular defense systems. During oxidative stress, antioxidative and detoxification
enzymes cannot protect cells against increased ROS production, leading to oxidative
damage in lipids, proteins and DNA. ROS production is increased during ageing and is
involved in the pathogenesis of many diseases, such as cardiovascular diseases, diabetes,
cancer and neurodegenerative diseases (Stocker, Keaney 2004, Droge 2002).
In  endothelial  cells,  oxidative  stress  leads  to  endothelial  dysfunction  and
activates other pathological processes such as apoptosis, monocyte aggregation and
migration. These processes advance vascular inflammatory processes, eventually leading to
atherosclerosis (Stocker, Keaney 2004, Madamanchi, Vendrov & Runge 2005, Yokoyama
2004).
2.2 ROLE OF THE ENDOTHELIUM IN ATHEROPROTECTION
The artery wall is formed from four layers: the endothelium, intima, media and adventitia,
each having specific roles in vessel function. The inner layer of the vessel wall, the
endothelium, functions as a physical barrier, regulates hemodynamics and angiogenesis,
synthesizes nitric oxide (.NO), and it inhibits inflammation and thrombosis. During ageing
and in the context of many clinical conditions, such as hypercholesterolemia, hypertension,
and diabetes, the endothelium is damaged and ROS production is increased. Rapidly
increased ROS production and decreased capacity of protective mechanisms leads to
endothelial dysfunction (Chiu, Chien 2011).
Dysfunctional endothelium cannot inhibit blood coagulation and vascular
inflammation,  and  the  regulation  of  cell  growth,  proliferation  and  organization  is
disrupted. Endothelial dysfunction also leads to increased vascular contraction, leukocyte
adhesion, platelet aggregation and thrombosis, and smooth muscle cell (SMC) proliferation
4(Figure 1). These effects are largely due to decreased bioactivity of .NO in the vessel wall
(Chiu, Chien 2011).
At the molecular level, decreased .NO bioactivity is caused by repressed
expression of endothelial specific nitric oxide synthase (eNOS), ROS production by eNOS,
or reduction of cofactors or increased reactions of .NO with ROS. The O2.- reaction with .NO
is three times faster than the reaction with SOD (Stocker, Keaney 2004). The main reaction
product of .NO and O2.- is peroxynitrite (ONOO-) that forms other radicals and maintains
oxidative stress (Stocker, Keaney 2004, Carr, McCall & Frei 2000). In addition to ONOO-
formation, .NO can be degraded to nitrite (NO2-) that functions as a substrate for
myeloperoxide to form nitrogen dioxide. Nitrogen dioxide can oxidize LDL, nitrate
lipoproteins (Carr, McCall & Frei 2000) or react with unsaturated lipids to form nitrated
fatty acids (O'Donnell et al. 1999). Nitrated fatty acids (NO2-FAs) activate antioxidative and
anti-inflammatory signaling to provide atheroprotective effects (Coles et al. 2002, Rudolph
et al. 2010a). Molecules derived from .NO are collectively termed as reactive nitrogen
species (RNS).
2.2.1 Shear stress
The force caused by unilateral blood flow (shear stress or laminar flow) is one of the main
factors maintaining normal endothelial functions. Shear stress protects the endothelium
from apoptosis and prevents atherogenesis, since areas where flow is turbulent are more
prone  to  lesion  formation  than  areas  subjected  to  laminar  flow.  Branches  of  the  blood
vessels and atherosclerotic lesions change the flow to turbulent, thus modifying the
biomechanical forces acting on the endothelium. Altered flow conditions affect the
expression profile of endothelial cells leading to the activation of adhesion and
inflammatory genes as well as the inhibition of protective genes. (Chiu, Chien 2011,
Gimbrone et al. 2000, Ross 1999, Traub, Berk 1998)
2.2.2 Endothelial dysfunction in atherogenesis
Atherosclerosis is a disease of medium and large arteries leading to the formation of fatty
streaks and finally fibrous plaques in the arterial wall. Oxidative stress has a role in all
stages of atherogenesis. The first manifestation of altered vascular homeostasis is
endothelial dysfunction, in which oxidative stress plays a significant role. The presence of a
high concentration of LDL in the circulation leads to the accumulation of LDL in the intima.
In the intima LDL is oxidized via enzymatic and nonenzymatic reactions forming
minimally  modified  LDL  (mmLDL)  and  oxidized  (oxLDL).  The  outer  layer  of  the  LDL
molecule is formed from phospholipids, cholesterol and apolipoprotein B100 (apoB100)
with  triglycerides  and  cholesterol  esters  inside.  In  mmLDL  phospholipids  of  LDL  are
mildly oxidized and proteins are intact or have minor modifications. Oxidation leads to
formation of oxLDL whereby in addition of highly oxidized phospholipids, apoB100 is
degraded and modified (Parthasarathy et al. 1999). Endothelial dysfunction increases the
expression of adhesion molecules on the surface of endothelial cells, which increases their
capacity  to  bind  monocytes.  Monocytes  bind  to  endothelial  adhesion  molecules  and
migrate into the intima where they are transformed to macrophages. Scavenger receptors of
macrophages recognize oxLDL, which is internalized and accumulates in cells, forming
foam cells. Foam cells form a fatty streak in the intima and secrete proinflammatory
cytokines that maintain chronic inflammation. Inflammation activates SMCs that migrate to
the intima from the media. In the intima, SMCs start to rapidly proliferate and produce
extracellular matrix molecules, such as collagen and elastin that cover the atheroma
forming a fibrotic (or advanced) plaque. Inside the plaque SMCs and lipid rich foam cells
can die, for example, via apoptosis. This leads to the release of the lipids into the
extracellular space and formation of the necrotic or lipid core. Over time, the fibrotic plaque
grows and can obstruct the artery, thus limiting blood flow. Plaque rupture can evoke
5thrombus formation that can disrupt blood flow locally or create emboli that may occlude
distal arteries (Libby, Ridker & Hansson 2011, Glass, Witztum 2001).
Figure 1. Shear stress and the role of endothelial dysfunction in atherogenesis. A, During
vascular homeostasis and shear stress, endothelial cells produce .NO, PGI2 (prostacyclin), tPA
(tissue plasminogen activator), thrombomodulin and TGF- (transforming growth factor-), that
mediate antithrombotic, antimigratory, growth inhibitory and prosurvival effects. B, Low shear
stress, ageing, and vascular diseases disrupt normal functions of endothelial cells leading to
changes in gene expression of the cells and endothelial dysfunction. The expression of
antithrombotic and antiapoptotic genes decreases, the migration of monocytes is increased via
induction  of  MCP-1  and  VCAM1,  and  the  growth  and  migration  of  the  SMCs  advances  via
induction  of  PDGF  (platelet-derived  growth  factor),  ANGII  (angiotensin  II),  and  endothelin-1.
These changes promote atherogenesis. Modified from (Traub, Berk 1998).
2.3 STRESS ACTIVATED SIGNALING PATHWAYS
ROS are generated during normal physiological functions, degenerative diseases and
ageing. Cells are adapted to the presence of ROS and multiple signaling pathways are
activated in response to ROS. Herein, the two important cytoprotective pathways activated
by ROS are discussed, namely the Keap1-Nrf2 pathway and the heat shock response (HSR).
62.3.1 Keap1-Nrf2 pathway
The Keap1-Nrf2 pathway is a protective signaling pathway, which is activated by oxidative
and electrophilic stress. The main players are transcription factor Nrf2 and Keap1, which
mediate proteasomal degradation of Nrf2. When activated, Nrf2 translocates to the nucleus
and binds to the ARE of its target genes.
2.3.1.1Nuclear factor E2-related factor 2
 Nrf2  (NFE2L2)  is  a  transcription  factor  activated  by  multiple  stimuli,  such  as  ROS,
electrophiles, xenobiotics, heavy metals, UV-radiation, and shear stress. Nrf2 belongs to the
cap’n’collar (CNC) family of transcription factors that have a common CNC-like basic
leucine zipper (bZip) domain. Other known members of the CNC family are Nrf1, Nrf3,
p45, BACH1, and BACH2. Via their CNC-domain, these factors dimerize with small Maf
proteins  and  bind  to  DNA.  Complex  formation  with  small  Mafs  is  essential  for  the
regulation of transcription. Nrf2 regulates the expression of antioxidant and phase II
detoxification enzymes (Zhang 2006).
The regulation of the NFE2L2 gene itself is poorly understood. Nrf2 protein is
expressed ubiquitously in all tissues and Nrf2-/- mice are viable (Chan et al. 1996, Itoh et al.
1997). It has recently been suggested that NFE2L2 expression in cancer cell lines is
regulated by Jun and Myc transcription factors (DeNicola et al. 2011). The translation of
NFE2L2  has  been  reported  to  be  inhibited  by  microRNAs  (miRNA)  miRNA-28  and
miRNA-144 (Yang et al. 2011, Sangokoya, Telen & Chi 2010).
The structure and regulation of the Nrf2 protein has been extensively
investigated. Nrf2 contains six NRF2-ECH homology domains (Neh1-Neh6, Figure 2) that
all have specific roles in protein function (Itoh et al. 1999). Neh1 contains CNC basic and
leucine zipper domains, which are critical for binding with small Maf proteins and the ARE
in the regulatory regions of target genes (Itoh et al. 1997). Lysine residues of Neh1 are also
acetylated by a co-transactivator, histone acetyltransferase p300/CREB-binding protein
(CBP) that regulates DNA binding (Sun, Chin & Zhang 2009). Protein stability is partially
regulated via Neh1 by ubiquitin-conjugating enzyme UbcM2 that binds to the cysteine
(Cys) 136 in the Neh1 domain. UbcM2 stabilizes Nrf2, enhances transcriptional activity and
has a cysteine residue that functions as a redox sensor (Plafker et al. 2010). Neh2 contains
ETGE and DLG motifs that serve as binding sites for the Nrf2 inhibitor protein Keap1
(Katoh et al. 2005, McMahon et al. 2006). Both domains are required for maximal
destabilization of Nrf2. Neh domains 3 to 5 are involved in Nrf2-mediated transcriptional
regulation. Neh3 contains the C-terminal end of the protein and takes part in the initiation
of transcription (Nioi et al. 2005). Neh4 and Neh5 bind CBP that further binds CREB (cAMP
responsive element binding protein I) to regulate the start of transcription (Katoh et al.
2001). Neh6 has a role in Keap1-independent degradation of Nrf2 during oxidative or
electrophilic stress (McMahon et al. 2004). Glycogen synthase kinase 3 phosphorylates the
serine residues of Neh6, leading to the SKP1-Cul1-F-box protein mediated ubiquitination of
Nrf2 (Rada et al. 2011). It has been proposed that these foregoing mechanisms mediate Nrf2
degradation when activated in strong stress conditions and when modified Keap1 is
incapable of degrading Nrf2, thus this may serve as an additional degradation mechanism.
Cellular localization of Nrf2 is regulated by nuclear export and localization
signals (NES and NLS) (Jain, Bloom & Jaiswal 2005, Li et al. 2005). NES and NLS direct
localization and nuclear export of Nrf2 in response to redox balance. Mutation studies have
shown that both localization signals are essential for the functions of Nrf2 protein. Deletion
of NLS inhibits nuclear translocation of Nrf2 and expression of target genes. Deficiency of
NES leads to the nuclear accumulation of Nrf2 and increased expression of target genes
(Jain, Bloom & Jaiswal 2005). NES and NLS sequences are recognized by chromosome
region  maintenance  (CRM1)  cargo  protein.  CRM1  binds  the  protein  and  transports  it
7through the membrane. Both localization signals are in the leucine zipper domain and are
also found in other CNC members (Suzuki et al. 2004).
Figure 2. Structure of Nrf2. Nrf2 contains six Neh domains,  each with specific  roles in protein
function. Neh2 contains DLG and ETGE motifs that bind with Keap1. Neh4 and 5 correspond to
transactivation,  Neh6  has  role  in  degradation,  and  Neh1  and  3  bind  small  Mafs  and  DNA.
Modified from (Kansanen et al. 2011).
2.3.1.2 Kelch-like ECH- associated protein 1
Nrf2 activation is mainly regulated by Keap1. Keap1 functions as a substrate adapter
protein between Nrf2 and Cullin 3 (CUL3)/Ring box 1 (RBX1)-dependent ubiquitin ligase
complex that mediates Nrf2 degradation (Figure 4) (Zhang et al. 2004, Kobayashi et al.
2004). The Keap1 structure contains four functional domains (Figure 3); the Broad complex,
Tramtrack and Bric a brac/ the poxvirus and zinc finger-domain (BTB/POZ), the intervening
region (IVR), the Kelch domain or double glycine repeat,and the C-terminal region.
BTB/POZ -domain is characteristic for BTB-protein family members as it enable them to
form protein-protein interactions (Zipper, Mulcahy 2002). The Kelch domain mediates
binding with Nrf2 (Kang et al. 2004). The Kelch domain contains six conserved -propeller
structures that were found from structural analysis of another Kelch-protein, galactose
oxidase, and two glycine repeats. Adjacent to the Kelch domain is an IVR and BTB that
house three cysteine residues (Cys151, Cys273, and Cys288) that are important for the
regulation of Nrf2 activity. The IVR- and BTB-domains also serve as a binding site for
CUL3-ubiquitin ligase that mediates the ubiquitination and proteosomal degradation of
Nrf2 (Kobayashi et al. 2004). Human Keap1 contains 27 and mouse Keap1 contains 25
cysteines whose alkylation or oxidation plays a major role in Keap1 mediated Nrf2
regulation (Dinkova-Kostova et al. 2002).
Figure  3.  Structure  of  Keap1. Functional  domains  of  Keap1  are:  BTB,  IVR,  Kelch  and  the  C-
terminal region. BTB and IVR mediate complex formation with CUL3 and the Kelch domain binds
with  Nrf2.  Modifications  of  Cys151,  Cys273,  and  Cys288  are  important  in  Nrf2  activation.
Modified from (Kansanen et al. 2011).
2.3.1.3 Keap1 mediated Nrf2 regulation
In basal conditions, Keap1 binds Nrf2 and functions as a substrate adaptor between Nrf2
and CUL3-ubiquitin ligase complex to mediate ubiquitination and proteosomal
degradation (Figure 4) (Zhang et al. 2004). Keap1 forms a homodimeric structure in the
cytosol that is essential for binding the Nrf2 and CUL3-complex (McMahon et al. 2006,
Furukawa, Xiong 2005). Keap1 molecules are bound to each other from BTB domains by
8forming a  cherry-bob-like  structure.  A DLG motif  in  the  Neh2 domain in  Nrf2  binds one
Kelch  domain  with  low  affinity  and  the  ETGE  motif  by  another  Kelch  domain  with  high
affinity, demonstrating that the DLG motif is an essential motif that provides the latch to
lock and unlock Nrf2 for ubiquitination (Tong et al. 2006, Tong et al. 2007). The
configuration of this complex activates ubiquitination of lysine residues located in the Neh2
domain. Ubiquitinated Nrf2 is rapidly degraded by the 26S-proteasome.
During oxidative or electrophilic stress, the cysteine residues of Keap1 are
modified via two alternative mechanisms. Mass spectrometry studies have revealed that
several Nrf2 activating agents bind to Keap1 cysteines. Different Nrf2 activating agents
affect different cysteines and there is no single cysteine that mediates the effects (Kansanen
et al. 2011, Kansanen, Kivela & Levonen 2009). The “cysteine code” hypothesis proposes
that structurally different Nrf2 activating agents affect different Keap1 cysteines. A
modification of Keap1 cysteines leads to the inhibition of Nrf2 ubiquitination via
conformational changes in the Keap1-Nrf2-CUL3 complex and translocation of Nrf2 to the
nucleus as presented in Figure 4 (Kobayashi et al. 2009). Modifications of Cys273 and 288
lead to a conformational change of Keap1 that disturbs the interaction between the DLG of
Nrf2 and the Kelch domain of Keap1 (Kobayashi et al. 2006). Lysine residues of Nrf2 are
thus no longer aligned for ubiquitination. Alternatively, when Cys151 located in the BTB
domain of Keap1 is modified, this modification leads to disruption between Keap1 and
CUL3 binding and hence, the Keap1-Nrf2-CUL3 complex itself (Rachakonda et al. 2008,
Eggler et al. 2009). Summarizing several mass spectrometry studies, it is well documented
that most of the Keap1 cysteines are modified by various electrophiles. However, contrary
to mass spectrometry, functional studies suggest that only Cys151, Cys273, and Cys288 are
important for regulation of Nrf2 (Kansanen, Kivela & Levonen 2009).
Nrf2 activation is regulated by a positive feedback loop via the expression of
the Nrf2 target gene p62/Sequestome 1. P62 is a protein that binds to multiple signaling
mediators upon a stress stimulus, and it is involved in autophagosome formation and
ubiquitination. It has been shown that p62 expression is Nrf2-dependent (Jain et al. 2010).
P62 can compete for the binding to the Kelch domain of Keap1 with the DLG motif of Nrf2,
thus leading to nuclear accumulation of Nrf2 and target gene expression (Komatsu et al.
2010). The DLG motif also binds p21, which is a regulator of cellular processes such as cell
cycle  arrest,  DNA  replication  and  repair,  and  cell  differentiation.  P21  stabilizes  Nrf2  and
p21 deficient mice have decreased expression of Nrf2-dependent genes (Chen et al. 2009).
Taken together, Nrf2 activation is stabilized by compensatory binding of p62 with Keap1
and binding of Nrf2 with p21. These results suggest that in addition to Keap1, there are
other players modulating Nrf2 degradation and activation.
2.3.1.4 Nrf2 activating agents
2.4.1.4.1 Classic Nrf2 activating agents (SFN, tBHQ, 15d-PGJ2)
Nrf2 is activated by multiple agents, such as phenol antioxidants, electrophilic compounds,
and heavy metals (Figure 5). Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane, SFN,
Figure 5A) is a naturally occurring isothiocyanate presented in cruciferous vegetables, such
as broccoli, having multiple anti-inflammatory and anti-oxidative effects. The effects of SFN
are mediated via regulation of transcription factors, for example by activation of Nrf2 and
inhibition of nuclear factor-B (NF-B) (Thimmulappa et al. 2002, Kivela et al. 2010). SFN
induces a large battery of antioxidant and detoxification genes (Thimmulappa et al. 2002).
In the endothelium, SFN induces protective genes during injury and inhibits inflammatory
genes via Nrf2 in vivo as well (Zakkar et al. 2009, Zhao et al. 2007). NF-B activation is
inhibited by SFN through several mechanisms such as via inhibition of tumor necrosis
factor- (TNF-) or lipopolysaccharide mediated phosphorylation of downstream signaling
mediators in the NF-B pathway (Kivela et al. 2010).
9Figure  4.  The  Keap1-Nrf2  pathway. Nrf2  is  bound  by  two  Keap1  proteins  that  function  as
adapters for the CUL3-ubiquitin ligase complex. In basal conditions, Nrf2 is rapidly ubiquitinated
and degraded. During electrophilic or oxidative stress, cysteine residues of Keap1 are modified
leading to the release of the Nrf2 DLG motif from Keap1. Nrf2 escapes degradation, translocates
to the nucleus and drives target gene expression via the ARE. Modified from (Kansanen et al.
2011).
Tert-butylhydroquinone (tBHQ, Figure 5B) is a phenol antioxidant that auto-
oxidizes and forms a semiquinone antioxidant radical. TBHQ activates Nrf2 dependent
gene expression to provide a protective role in many tissues, including endothelial cells
(Lee et al. 2003, Li et al. 2007). Both SFN and tBHQ activate Nrf2 via modification of the
Keap1 Cys151 (Zhang, Hannink 2003, Wang et al. 2008).
15-deoxy-12,14-prostaglandin J2 (15d-PGJ2, Figure 5C) is a J series prostaglandin
produced by the cyclooxygenase (COX) pathway from prostaglandin D2 in a nonenzymatic
dehydration reaction. 15d-PGJ2 forms covalent adducts with thiol residues of proteins, thus
it has a role in multiple signaling pathways. One of the targets of 15d-PGJ2 is Keap1 Cys273
and probably also Cys288 (Kobayashi et al. 2009, Levonen et al. 2004). Adduction of 15d-
PGJ2 to the Keap1 Cys273 leads to Nrf2 activation. Unlike with SFN and tBHQ, the effect of
15d-PGJ2 is Cys151-independent and do not involve Keap1-CUL3-dissociation (Kansanen et
al. 2011). Via activation of Nrf2-Keap1 signaling, 15d-PGJ2 has cytoprotective features
(Kansanen, Kivela & Levonen 2009).
2.3.1.4.2 Oxidized phospholipids
Phospholipids are structural components of lipid layers in cell membranes and lipoproteins
and can be oxidized through the lipoxygenase and myeloperoxidase pathways to form
biologically active oxidized phospholipids (oxPLs). Phospholipids are hetoregenous group
with variations in sn2- and sn3-residue fatty acids, so therefore during oxidation and
fragmentation, numerous different lipid molecules are formed. A lipid layer derived of
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oxPLs can be formed inside of cells and has local effects such as activation of the
endoplasmic reticulum stress response (Gargalovic et al. 2006a). A large amount of oxPLs
are  formed  via  oxidation  of  LDL.  OxPLs  can  be  cleaved  out  from  mmLDL  or  oxLDL
molecules, or oxPLs can be recognized as a part of the molecule. It has been demonstrated
that oxPLs go into the endothelial cells, but the precise mechanisms of this are unclear. It
has  been  suggested  that  oxPLs  as  small,  lipophilic  molecules  can  go  straight  through
membranes. Receptors such as the scavenger receptor CD36 can recognize and bind to
oxPLs (Bochkov et al. 2010, Gao et al. 2010). OxPLs are present at high concentrations in
atherosclerotic vessels and lesions, and it has been suggested that oxPLs are involve in all
stages of atherogenesis (Bochkov et al. 2010). It has been estimated that 10 to 20% of total
lipids of the atheroma are different species of phospholipids (Ravandi et al. 2004).
One  of  the  oxPLs  in  mmLDL  is  oxPAPC.  The  most  abundant  and  well
characterized oxidation products of PAPC are 1-palmitoyl-2-oxovaleryl-sn-glycero-3-
phosphocholine (POVPC), 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC),
and 1-palmitoyl-2-(5, 6 epoxyisoprostanoyl)-sn-glycero-3-phosphocholine (PEIPC) (Figure
6) (Navab et al. 2004).
OxPAPC activates protective, inflammatory and apoptotic pathways. In the
vascular endothelium it induces the expression of inflammatory molecules and adhesion
molecules to increase the binding of monocytes in murine arteries (Furnkranz et al. 2005). It
also  induces  oxidative  stress  by  Nox  mediated  O2.- production in endothelial cells
(Rouhanizadeh et al. 2005). The unfolded protein response (UPR) is a signaling pathway
activated by stress via the endoplasmic reticulum or by oxPAPC (Gargalovic et al. 2006a).
The UPR response can activate three adaptive or proapoptotic signaling pathways
regulated by immunoglobulin binding protein/glucose regulated protein 78 that is an
endoplasmic reticulum resident chaperone locking downstream signaling mediators such
as activating transcription factor-6, inositol requiring protein 1, and double-stranded RNA-
dependent protein kinase (PKR)-like endoplasmic reticulum kinase (PERK). UPR activation
leads to chaperone activation, release of signaling factors and regulation of UPR target
genes (Ron, Walter 2007). OxPAPC activates all branches of UPR in human aortic
endothelial cells, mediating angiogenesis and vascular inflammation by activating
transcription factor-4 and X-box binding protein-1 signaling pathways, which are
downstream factors of the PERK and inositol requiring protein 1 pathways respectively
(Gargalovic et al. 2006a, Bochkov et al. 2006, Gargalovic et al. 2006b, Oskolkova et al. 2008).
In the vascular endothelium it has been demonstrated that oxPAPC induces the expression
of ARE regulated protective genes (Li et al. 2007, Gargalovic et al. 2006a, Gargalovic et al.
2006b).  OxPAPC  induces  HO-1  and  GCL  in  human  endothelial  cells  (Gargalovic  et  al.
2006b). Nrf2 has been shown to be activated by oxPAPC and to induce the expression of the
ARE-mediated gene oxidative stress induced growth inhibitor 1 (Li et al. 2007).
Different fractions of oxPAPC have different biological effects and they can
also modulate the functions of other oxPL species. When the effects of oxPLs on the
activation of the UPR were studied, results showed that the oxidized sn2-residue has a
critical role (Oskolkova et al. 2008, Subbanagounder et al. 2000). It has also been
demonstrated that high density lipoprotein modifies the effects of oxPAPC and PEIPC by
inhibiting proinflammatory signaling and maintaining antioxidant activities (Gharavi et al.
2007).
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Figure  5.  Structures  of  selected  Nrf2  activating  agents. A,  sulforaphane  (SFN);  B,  tert-
butylhydroquinone (tBHQ); C, 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2); D, nitrated oleic
acid (OA-NO2).
2.3.1.4.1 Nitrated lipids
Nitrated fatty acids (NO2-FAs) are electrophilic fatty acid derivates that are formed via
reactions  of  RNS,  such as  an .NO, NO2-, or ONOO- with unsaturated fatty acids. Nitrated
linoleic acid (LNO2) and oleic acid (OA-NO2, Figure 5D) have a role as signaling mediators
by the induction of protective signaling, such as Keap1-Nrf2-, and peroxisome proliferator
activated receptor (PPAR)-  pathways,  and  on  the  other  hand,  by  inhibiting  the  NF-B
pathway (Koenitzer, Freeman 2010). LNO2 and OA-NO2 modify proteins post-
translationally to form covalent adducts with thiol residues (Baker et al. 2007). NO2-FAs
activate the Nrf2 pathway independently of Keap1 Cys151; instead Cys273 and Cys288
seem to be functionally important for this Nrf2 activation and Nrf2-dependent gene
expression (Kansanen et al. 2011, Tsujita et al. 2011). The formation of LNO2 and OA-NO2
has been demonstrated also in vivo after ischemia-reperfusion injury (I/R) (Rudolph et al.
2010b). Administration of NO2-FA protects against I/R, inhibits neointima formation and
NF-B mediated inflammation, showing a protective and antiatherogenic role for NO2-FAs
in the cardiovascular system (Rudolph et al. 2010a, Cole et al. 2009).
Figure  6.  Structures  of  the  oxidation  products  of  PAPC. A, 1-palmitoyl-2-arachidonoyl-sn-
glycero-phosphocholine (PAPC), B, 1-palmitoyl-2-(5,6 epoxyisoprostanoyl)-sn-glycero-3-
phosphocholine (PEIPC), C, 1-palmitoyl-2-oxovaleryl-sn-glycero-3-phosphocholine (POVPC),
D, 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC).
2.3.1.4 Posttranslational modifications of Nrf2
Phosphorylation has a general role in the activity and stability of proteins. Nrf2 has been
demonstrated to be phosphorylated by protein kinase C, extracellular signaling-regulated
kinase, p38 mitogen-activated kinase and during endoplasmic reticulum stress, by PERK.
Protein kinase C phosphorylates the serine 40 residue in the Neh2 domain of Nrf2 but this
is not necessary for nuclear translocation and target gene expression (Bloom, Jaiswal 2003,
Huang, Nguyen & Pickett 2000). Nevertheless, it seems to disturb Keap1 mediated
ubiquitination (Huang, Nguyen & Pickett 2002). PERK mediates phosphorylation and
activation of Nrf2 during endoplasmic reticulum stress, contributing to cell survival
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(Cullinan et al. 2003, Cullinan, Diehl 2004). However, the studies that examine the roles of
different kinase pathways on Nrf2 activation have somewhat controversial results. The role
of kinases seems to be dependent on cell types and target genes. Phosphorylation of
dimerization partners and co-activators may have a role in the transcriptional regulation of
ARE regulated genes (Kensler, Wakabayashi & Biswal 2007).
Nrf2 has been demonstrated to be acetylated by p300/CBP via lysine residues
located in Neh1 (Sun, Chin & Zhang 2009). P300/CBP is known to be a co-transactivator of
Nrf2 and essential for DNA binding and transactivation. Sun and colleagues (2009) showed
that p300/CBP has a function as a histone acetyltransferase and it stabilizes Nrf2 via
acetylation of lysine residues. Acetylation increases and stabilizes transactivation, but it is
not obligatory. Acetylation does not have any effect on the ubiquitination or degradation of
Nrf2.
2.3.2 Heat shock response
HSR is a common cellular defense mechanism turned on by a wide array of acute and
chronic  stress  conditions.  HSR  is  highly  conserved  and  it  has  been  found  from  yeast  to
mammalian cells. HSR is regulated by heat shock factors (HSFs) that bind to the heat shock
response element (HSE) on the promoters of target genes upon activation. Mammalian cells
express three HSFs; 1, 2, and 4. HSF3 is avian-specific. HSF1 is the first factor identified and
is also the best studied. It is activated by elevated temperatures, exposure to oxidants and
heavy metals, or by bacterial or viral infection. HSF1 is a transactivator and other HSFs
cannot compensate for its functions. HSF2 is involved in development and differentiation
processes, and HSF4 is recently characterized and expressed mainly in the lens of the eye
and in the brain (Akerfelt et al. 2007).
HSF1 activation is a multistep process where it trimerizes, translocates to the
nucleus,  and  binds  to  the  HSEs  on  target  genes.  Post-translational  modifications  have  an
important role in the regulation of HSF1. Under basal conditions, HSF1 is a monomer that
is phosphorylated via multiple serine and lysine residues. Upon activation, HSF1
undergoes a transition from a monomer to a trimer and binds to the regulatory regions of
target genes. For DNA binding, HSFs contain DNA-binding domains. HSFs bind to the
DNA in sites where each of the DNA-binding domains faces the HSE. HSEs are highly
conserved and contain multiple repeats of the pentameric sequence nGAAn. Target genes
often have multiple HSEs that are able to bind several HSFs at the same time (Akerfelt,
Morimoto & Sistonen 2010). HSR activated genes and heat shock proteins (HSPs) function
as chaperones, proteases, or essential protectors against proteotoxic stress (Akerfelt et al.
2007).
Post-translational modifications regulate HSF1 functions and activity.
Phosphorylation and sumoylation positively regulate activity (Akerfelt et al. 2007, Akerfelt,
Morimoto & Sistonen 2010). It has also been proposed that HSF2 has a function as a
modulator of HSF1 (Ostling et al. 2007). The activation of HSF1 is negatively regulated by
feedback mediated by HSPs and by acetylation of a lysine residue located in the DNA
binding area (Akerfelt, Morimoto & Sistonen 2010).
HSP90 has been demonstrated to play role in protective signaling via inhibition
of Keap1. Casein kinase 2 phosphorylates threonine residue of Keap1 serving a binding site
for HSP90. Keap1-HSP90 interaction leads to the disruption of the Keap1-CUL3-ubiquitine
ligase complex, release of Nrf2 for degradation and target gene expression (Niture, Jaiswal
2010).
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2.4 NRF2 MEDIATED GENE REGULATION
2.4.1 Small Maf proteins-dimerization partners of Nrf2
Upon oxidative or electrophilic exposure, Nrf2 translocates to the nucleus and
heterodimerizes with small Maf protein family members (Itoh et al. 1995). The Maf protein
family is named according to the first member found, v-Maf oncogene (Musculo
Aponeurotic Fibrosarcoma virus), and contains either large or small Mafs. All Mafs contain
a bZip domain and an extended homology region that mediates DNA binding. Large Mafs
are transcription factors that regulate tissue-specific gene expression and cellular
differentiation in mammals. Small Mafs; MafG, MafK, and MafF, are highly homologous,
small proteins (18 kDa), lacking the transactivation domain (Blank 2008). Several CNC
family transcription factors heterodimerize with small Mafs and bind to the Maf
recognition element (MARE) or ARE (Itoh et al. 1997, Itoh et al. 1995). Even though small
Mafs cannot work as independent transactivators; they have a remarkable role as
modulators of gene regulation. Small Mafs modulate gene expression via the CNC-family
transcription factors and by inhibiting expression by binding to the target regulatory
regions as homodimers (Kataoka et al. 1995a). The effects of small Mafs on gene expression
have  been  studied  by  using  small  Maf  knockout  mice  and  cells.  Knocking  down  an
individual small Maf has no effect on the viability of mice. Deficiency of MafG and MafK
together leads to severe defects in erythroid cell development and the defective capability
of antioxidant and detoxification gene induction. The life span of those mice was short.
Deficiency of all three small Mafs is lethal during embryogenesis (Blank 2008).
The regulation of small Maf genes is complex and has both temporal and
tissue-specific variation. The MafG gene is regulated by electrophilic insults via Nrf2,
serving as an autoregulatory feedback loop (Katsuoka et al. 2005). The MafK gene contains
two brain tissue-specific promoters and specific enhancer areas for expression in
hematopoietic and cardiac tissues. The promoter of MafF contains three promoter areas
with unknown functions (Blank 2008). In addition to the regulation of gene expression,
MafG is also post-translationally modified by acetylation and sumoylation. Acetylation is
mediated  by  CBP  and  it  increases  the  DNA  binding  activity  of  MafG  (Hung  et  al.  2001).
Extended homology region is a site for sumoylation and it is suggested that sumoylation
plays a role in MafG mediated gene repression (Motohashi et al. 2006). Post-translational
modifications are not essential but enhance MafG function and it is suggested that such
modifications modulate functions of all Mafs (Blank 2008).
2.4.2 Antioxidant response element
In  the  nucleus,  the  Nrf2-small  Maf  heterodimer  binds  to  the  ARE  (also  called  the
electrophile response element, EpRE) in the regulatory region of target genes (Itoh et al.
1997, Itoh et al. 1997). Rushmore et al (1991) made the first identification of the ARE core as
5’-RGTGACnnnGC-3’  (n  =  A,  C,  G,  or  T)  (Rushmore,  Morton  &  Pickett  1991).  They  also
identified cis-acting features  and the  response to  oxidative  stress  by studying the  ARE of
the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene. Wasserman & Fahl, by studying the
ARE of the glutathione S-transferase gene, concluded that nucleotides outside of the
previously identified core sequence are essential for inducible expression, and suggested a
longer core sequence, 5’-TMAnnRTGAYnnnGCRwwww-3’ (M = A or C, R = A or G, Y = C
or T, w = A or T, core sequence underlined) (Wasserman, Fahl 1997). Erickson et al further
studied the ARE of the glutamate-cysteine ligase modifier subunit (GCLM) and noticed that
there is more variation than in the ARE core identified previously. The core sequence was
modified to 5’-RTKAYnnnGCR-3’ (K = G or T, Y = C or T) (Erickson et al.  2002).  Later on,
Nioi et al reported that a G at Wassermans position 14 is not essential (Nioi et al. 2003). It
was  concluded  that  there  is  no  universal  ARE  core  sequence  and  that  the  ARE  sequence
varies among genes and species.
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Single nucleotide polymorphisms (SNPs) in transcription factor binding sites may affect the
binding of transcription factors and gene regulation. Human ARE SNPs were identified in a
study  where  a  position  weight  matrix  (PWM,  Figure  7)  for  the  identification  of
polymorphic AREs was generated. PWM identified SNPs that may be important in the
regulation of an Nrf2-dependent response. PWM can be used as a computational tool for
searching and estimating functionality of putative AREs in the promoters of novel ARE
regulated genes (Wang et al. 2007). SNPs in AREs may also play a role in susceptibility and
pathogenesis of diseases.
The ARE consensus sequence has an internal activator protein-1 (AP-1) -
binding site (5’-TGAC-3’), challenging the identification of ARE target genes. However AP-
1 binding factors are not capable of binding ARE with high enough affinity that would
promote transcription. Also, the reporter assay studies have demonstrated that the
elements are activated by different stimuli (Nguyen, Sherratt & Pickett 2003).
An ARE serves as a binding site for multiple CNC-family transcription factors
that regulate both basal and inducible expression of target genes. The same target gene can
be regulated via an ARE by different transcription factors due to various stimuli and may
be either transactivated or repressed (Kim et al. 2001).
Figure 7. Antioxidant response element position weight matrix. The size of the letter describes
the importance of the nucleotide, generated in WebLogo
(http://weblogo.berkeley.edu/logo.cgi).
2.4.3 BTB and CNC homology 1-a negative regulator of ARE
The activation of an ARE is known to be repressed by the CNC-family transcription factors,
BACH1 and BACH2, and by small Maf protein homodimers. BACH1 and BACH2 are CNC
transcription factor family members that have a repressive function. Via a CNC/bZip-
domain, the BACH proteins dimerize with small Mafs and bind to DNA. At the N-terminal
end, BACH proteins have a BTB-domain that mediates homodimerization. The function of
homodimerization is unknown (Ito et al. 2009). BACH proteins form heterodimers with
small Maf proteins, mainly with MafK, and regulate gene expression via competitive
binding to the MARE. MARE is a regulatory element closely related to an ARE, with a main
function of regulating proliferation and differentiation (Oyake et al. 1996). The functions of
BACH2 are less studied. BACH2 is expressed in developing neuronal cells and B cells and
it has a role in antibody class switching and antibody response. In oxidative stress, BACH2
counteracts Nrf2 and induces apoptosis (Igarashi, Sun 2006).
Transcriptional regulation of the BACH1 gene is poorly understood. There are
three transcript variants (1, 2 and 3) of the BACH1 gene. Isoform A is a functional protein
coded by transcript variants 1 and 2, which have different 5' untranslated regions (UTRs).
Isoform B, translated from transcript variant 3, differs from the other two by having a
distinct 5' UTR, 3' coding region and 3' UTR, resulting in a shorter protein that lacks DNA
binding properties (Kanezaki et al. 2001). It has been suggested that the shorter isoform
recruits the longer active isoform to the nucleus through the interaction with the BTB
domain.
The mouse Bach1 gene contains two guanine-cysteine boxes in the promoter
which bind Sp1. Sp1 regulates basal transcription of mouse Bach1 (Sun et al. 2001). The
same study reported a putative ARE-like element downstream of the transcription start site
(TSS).  However,  the  functionality  of  this  element  was not  fully  addressed.  In  human and
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mouse hepatic cell lines, BACH1 expression has been shown to be induced by an Nrf2
activating  agent,  tBHQ,  both  at  the  mRNA  and  protein  levels.  This  suggests  that  BACH1
might be an Nrf2 target gene (Kaspar, Jaiswal 2010). The human BACH1 gene has also been
suggested to contain a hypoxia response element based on the observations that Bach1
mRNA is induced in hypoxic conditions (Kitamuro et al. 2003). Translation of BACH1 is
reported to be negatively regulated by miRNA-196 and miRNA-155, leading to the up-
regulation of hemi oxygenase-1 (HO-1) (Hou et al. 2010, Yin et al. 2008).
BACH1 protein is regulated by phenolic antioxidants, oxidative stress and
heme. BACH1 contains five cysteine residues near the CNC/bZip domain (Figure 8).
Cys574 is modified by oxidative stress, leading to the nuclear export and release of the
ARE. It has been proposed that the redox state of cysteine residues is critical for DNA
binding and oxidation can trigger dissociation of BACH1 from its target sequence
(Ishikawa, Numazawa & Yoshida 2005). Increased phosphorylation of tyrosine 486 caused
by phenolic antioxidants leads to the nuclear export of BACH1, allowing Nrf2 to bind to the
target  gene  AREs.  Subsequently,  BACH1  is  induced  and  de  novo  synthesized  BACH1
translocates to the nucleus (Kaspar, Jaiswal 2010). Heme binds to the C-terminal region of
BACH1 where it has four dipeptide cysteine-proline (CP) motifs (Figure 8). Binding of
heme to BACH1 inhibits DNA binding (Ogawa et al. 2001). Heme also triggers nuclear
export of BACH1, mediated by NES and CRM1 (Suzuki et al. 2004), leading to the
ubiquitination and degradation of BACH1 (Zenke-Kawasaki et al. 2007). BACH1 also
regulates cellular senescence via negative regulation of p53. BACH1 forms a complex with
p53 and histone deacetylase 1 that leads to the repression of p53 target genes (Dohi et al.
2008). Cellular senescence caused by oxidative stress is inhibited by BACH1 mediated
modulation of the p53 pathway (Ota et al. 2011).
Relatively little is known about the target genes of BACH1. BACH1 lacks a
transactivation domain and it is therefore unable to support transcription (Igarashi et al.
1998, Igarashi et al. 1998). The expression of -globin is regulated via a locus control region
during differentiation, when BACH1 is one of the players (Igarashi, Sun 2006). Under low
cellular heme concentration or unstressed conditions, BACH1 binds to the -globin ARE
sequence, thereby repressing gene expression. BACH1 competes with Nrf2 for the ARE
binding site. One of the main targets of BACH1 is HO-1, which is tightly regulated by
BACH1 under physiological conditions (Sun et al. 2002, Reichard, Motz & Puga 2007,
Reichard, Sartor & Puga 2008). BACH1 plays a role in turning off HO-1 expression after the
induction. In hepatocytes, BACH1 regulates the expression of NQO1 and thioredoxin
reductase 1 (TXNRD1) in response to tBHQ (Dhakshinamoorthy et al. 2005, Hintze et al.
2007). However, there are controversial results regarding TXNRD1 as a putative BACH1
target gene (Reichard, Motz & Puga 2007). A high-throughput sequencing study with
BACH-chromatin immunoprecipitation (ChIP) combined with microarrays suggests that
BACH1 has a more significant role in the regulation of metabolism and signal transduction
than  was  previously  thought.  The  study  identified  59  genes  that  were  bound  by  BACH1
and up-regulated by the siRNA against BACH1. The new target genes are involved in cell
proliferation and neurodegenerative processes (Warnatz et al. 2011). The importance of
BACH1  in  proliferation  is  also  evident  in  vivo.  Neointima  formation  in  BACH1  deficient
mice was significantly less than in wild type mice in the vascular cuff model (Omura et al.
2005). Deficiency of BACH1 in atherosclerosis-prone apolipoprotein E deficient mice (ApoE-
/-) mice demonstrated that BACH1 has a role in atherosclerotic lesion formation via
inhibition of HO-1 (Watari et al. 2008). However, BACH1 may not be a universal negative
regulator of the ARE-dependent genes and there may be cell type specific differences in the
regulation (Warnatz et al. 2011).
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Fig 8. Structure of the BACH1 protein. BACH1 domains include BTB, bZip, a C-terminal domain
and  six  CP  motifs.  BTB  mediates  homodimerization,  bZip  helps  homodimerization  with  small
Mafs, and four C-terminal CPs form a binding site for heme. NLS is localized to the bZip domain
and heme regulated NES in CP motifs. Modified from (Igarashi, Sun 2006).
2.5 VASCULAR EFFECTS OF NRF2 AND ITS TARGET GENES
2.5.1. Role of Nrf2 in shear stress
In  arteries,  Nrf2  is  activated by shear  stress,  the  force  caused by normal  blood flow.  This
leads to ARE activation, induction of target genes, and Nrf2-dependent inhibition of
vascular cell adhesion molecule 1 (VCAM1) (Chen et al. 2003). Instead, in endothelial cells
of areas with low shear stress, Nrf2 is not activated and cells are susceptible for atherogenic
changes (Zakkar et al. 2009).
The mechanisms by which Nrf2 is activated by shear stress have been explored
to some degree. One possible mechanism is COX-2 mediated production of the Nrf2
activating agent, 15d-PGJ2, which is increased by shear stress (Hosoya et al. 2005). It has
been proposed that Nrf2 activation during shear stress protects against ROS and RNS
mediated inflammation. Production of ROS and RNS is increased in low shear areas, where
Nrf2 expression is decreased (Takabe, Warabi & Noguchi 2011). Upon shear stress ROS and
RNS are produced at low levels, thus maintaining Nrf2 activation directly or via initiation
of lipid peroxidation (Takabe, Warabi & Noguchi 2011). Nrf2 activation inhibits TNF-
mediated induction of VCAM1 and monocyte chemoattractant protein 1 (MCP1) (Chen et
al. 2003, Hosoya et al. 2005). SFN mediated Nrf2 activation inhibits VCAM1 expression via
suppression of p38-signaling both in endothelial cell cultures as well as in murine arteries
at low shear stress areas (Zakkar et al. 2009). Shear stress also induces the expression of
Krüppel-like factor 2 that enhances Nrf2 activation (Fledderus et al. 2008).  In summary, the
activation of Nrf2 by shear stress plays an anti-atheroprotective role in the vascular
endothelium by maintaining cellular redox homeostasis.
2.5.2 Role of Nrf2 in atherogenesis
The role of Nrf2 in atherogenesis is not fully established. The protective effects of Nrf2 are
largely mediated by its target genes, HO-1 and glutamate-cysteine ligase (GCL), the rate-
limiting enzyme of glutathione (GSH) synthesis (Ishii et al. 2004, Bea et al. 2003). In
endothelial cells, Nrf2 has role in the protection and maintenance of physiological
homeostasis induced by shear stress. In macrophages, Nrf2 dependent HO-1 activation
inhibits lipopolysaccharide mediated inducible NOS expression (Kuhn et al. 2011). Nrf2
also plays a role in macrophage phenotype transformation in the intima. OxPAPC has been
proposed to modify macrophage phenotype via Nrf2. This novel phenotype is specific for
atherosclerotic  lesions  (Kadl  et  al.  2010).  On  the  other  hand,  it  has  been  shown  that  Nrf2
increases the expression of the CD36 scavenger receptor of macrophages that recognizes
oxLDL leading to increased foam cell formation (Ishii et al. 2004).
In SMCs, Nrf2 inhibits proliferation in addition to the protective functions
mediated by target genes (Anwar et al. 2005). Nrf2 dependent inhibition of proliferation has
also  been  shown  in  vivo  in  the  rabbit  aortic  balloon  injury  model.  Local  adenoviral  Nrf2
over-expression inhibits SMC proliferation, oxidative stress, and inflammation. However,
Nrf2 over-expression does not affect neointima hyperplasia. The reason for this might be
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that the survival of cells is improved even if the proliferation rate is decreased (Levonen et
al. 2007).
In an atherosclerotic mouse model ,ApoE-/-,  instead,  the  lack  of  Nrf2  protects
against atherosclerosis. It has been suggested that this is because of Nrf2-dependent
induction of CD36, which leads to increased oxLDL uptake and accelerated atherogenesis
(Barajas et al. 2011, Sussan et al. 2008). However, there are no reports from other
physiological models of atherosclerosis.
2.5.3 General role and vascular features of Nrf2 target genes
Nrf2 is a strong transactivator that regulates basal and inducible expression of antioxidant
and detoxification enzymes. Nrf2 target genes are involved in glutathione synthesis, ROS
and RNS elimination, xenobiotic metabolism, and drug transport. The development of new
sequencing techniques has offered a new platform to study the targets of transcription
factors. The Nrf2 dependent gene expression battery has been studied by microarray based
expression profiling and high-throughput sequencing in combination with Nrf2-ChIP.
Studies confirm the role of Nrf2 as a protector against toxic conditions and also highlight
the less studied role of Nrf2 in proliferation control (Malhotra et al. 2010). Nrf2 is
ubiquitously expressed in the vasculature. Herein, the functions of selected target genes
and their roles in vascular biology and pathogenesis are reviewed.
2.5.3.1 Glutathione system
GSH is one of the most important antioxidants in human cells. The intracellular
concentration of  GSH is  between 1-5  mM depending on the  cell  type.  GSH functions  as  a
cofactor for an H2O2 metabolizing enzyme, glutathione peroxidase, and as an electron
transporter in Glutathione-S-transferase catalyzed detoxification reactions, for neutralizing
xenobiotics and their metabolites. The rate-limiting enzyme of GSH synthesis is GCL that
has two subunits; catalytic and modifier subunits (GCLC, GCLM). GCL catalyzes the
reaction of glutamate and cysteine. The cellular level of GSH regulates the enzymatic
activity of GCLC, thus this provides a negative feedback system (Huang et al. 1993). GCLM
regulates the kinetic features of GCLC catalyzed reactions by decreasing the saturation
constant of glutamate and by elevating the GSH inhibition constant. The role of GCLM
becomes important when concentrations of glutamate and cysteine decrease below the
physiological rate levels (Huang, Anderson & Meister 1993). In the next step, glycine is
added to the -glutamylcysteine in a reaction catalyzed by glutathione synthetase,
producing the end product GSH.
Genes coding GCLC and GCLM are regulated by multiple transcription factors
and promoter elements, such as Nrf2 and AP-1 (Dickinson et al. 2004). Functional
transcription factor and response elements are dependent on activating conditions and cell
types. The Nrf2-ARE -signaling is one of the main regulatory pathways. Both GCLC and
GCLM contain AREs (Ericson a 2002). The levels of GCLC and GCLM are decreased in Nrf2
deficient tissues and cells.
GCL deficiency or poor functionality leads to the decrease or even loss of GSH
synthesis. GCLC-/- mice  completely  lack  GSH  synthesis,  which  is  lethal  during
embryogenesis. GCLM-/- mice  do not  have a  clear  phenotype,  but  their  GSH and cysteine
levels are reduced compared to wild type mice (Yang et al. 2002). GCLM-/- mice are also
more sensitive to the effects of oxidative stress. GCLC and GCLM promoter
polymorphisms have been identified (Koide et al. 2003, Nakamura et al. 2002).
Polymorphisms decrease inducible GSH synthesis, which impairs cellular defense against
oxidative stress. Deficiency of GSH also decreases the sensitivity of endothelial cells to .NO
and promotes endothelial dysfunction. Such polymorphisms are also associated with a
higher risk of myocardial infarction in humans (Nakamura et al. 2003).
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2.5.3.2 Heme oxygenase-1
HO-1 is an enzyme involved in heme degradation that has multiple protective effects. HO-1
is activated by a host of different activators and stress conditions. The basal activity of HO-
1 is repressed during cellular homeostasis by BACH1 and the inducible activity is highly
regulated by Nrf2. Both the repression in basal conditions and inducible expression during
cellular stress are mediated by the ARE (Alam et al. 1999). The HO-1 promoter carries two
ARE regions, the proximal and distal enhancers. BACH1 and Nrf2 bind both AREs of HO-1,
but bind the distal ARE with higher affinity and in a reciprocal manner (Reichard, Motz &
Puga 2007). In addition to the Nrf2-ARE pathway, other transcription factors and
regulatory elements take part in the inducible expression of HO-1 (Alam et al. 2004). The
effects of HO-1 are mediated via a reaction in which heme is metabolized to biliverdin and
further to bilirubin by biliverdin reductase. The reaction also produces carbon monoxide
(CO) and iron. CO plays a role as a signaling molecule especially in vascular cells and it has
an important role in cardiovascular diseases. CO is anti-inflammatory, it prevents platelet
aggregation,  and  it  inhibits  apoptosis  of  endothelial  cells  and  fibroblasts.  Thus  CO  is  an
anti-inflammatory and antiapoptotic molecule in the vasculature. The free iron released is
stored as ferritin. Bilirubin is an important antioxidant that has a role as a scavenger of lipid
peroxides (Otterbein et al. 2003).
Polymorphisms of human HO-1 promoter guanine-thymine-repeats are
associated with cardiovascular diseases. Studies in the Japanese population have suggested
that the lengthening of guanine-thymine-repeats in the presence of other risk factors
associates with increased prevalence of atherosclerosis (Kaneda et al. 2002). In human
atherosclerotic lesions, HO-1 expression is increased and the expression level correlates
with the increased expression of proinflammatory genes. In a mouse study, HO-1 promoted
progression of the plaque by increasing the thickness of the fibrous cap and by enhancing
SMC accumulation. In contrast, the necrotic core area and lipid deposition inside of the
plaque was reduced. These effects were due to HO-1 mediated protection of SMC survival
that leads to increased plaque stability (Cheng et al. 2009).
2.5.3.3 NAD(P)H: quinone oxidoreductase-1
NQO1 is quinone and quinoneimide detoxifying enzyme, and its expression is regulated
via ARE both in basal conditions and during oxidative stress. Nrf2 deficiency impairs the
constitutive expression of NQO1 and inhibits its induction, and NQO1 is often referred to a
classical Nrf2-dependent gene (Nioi, Hayes 2004).
NQO1 also has a function in recycling cellular antioxidants, vitamin E and
ubiquinone, after radical attacks. Quinones are reactive molecules found in exhaust fumes
and cigarette smoke that cause DNA damage leading to cancer and neurodegenerative
diseases. Partially reduced quinones produce O2- and H2O2 in a redox cycle. The injurious
effects of quinones are a consequence of their metabolism in one electron chain reaction,
catalyzed by p450 enzymes. The reaction produces a molecules containing oxygen with a
highly reactive unpaired electron that leads to the formation of new radicals. In reactions
catalyzed by NQO1, two electrons of the target molecule are reduced, and then a stabile
molecule is formed and conjugated to the secretory product (Nioi, Hayes 2004). Ubiquinone
and vitamin E are important liposoluble antioxidants that protect cells against lipid
peroxides. NQO1 reduces ubiquinone to ubiquinolol (Nioi, Hayes 2004). Vitamin E is
converted to -tokoferolquinone during a radical attack and further to -
tokoferolhydroquinone in an NQO1 catalyzed reaction. -tokoferolhydroquinone is an
antioxidant that protects cell membranes during injury (Siegel et al. 1997). NQO1 also has a
role  in  stabilizing p53 by inhibiting its  degradation via  an unknown mechanism.  As well,
NQO1-/- mice express lower levels of p53 compared with controls (Long et al. 2002). These
studies demonstrate the important role of NQO1 in cancer prevention (Nioi, Hayes 2004).
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Recently, the role of NQO1 in vascular diseases has been studied and it has been proposed
that NQO1 plays a role in the development and progression of atherosclerosis via
regulation of SMC proliferation. Pharmacological induction of NQO1 has also been shown
to prevent arterial restenosis via inhibition of SMC proliferation (Kim et al. 2009). It has also
been demonstrated that single nucleotide polymorphisms in NQO1 lead to a decreased
level  of  functional  protein  and  are  associated  with  carotid  artery  plaques  in  type  two
diabetic patients (Han et al. 2009).
2.5.3.4 Thioredoxin system
2.5.3.4.1 Thioredoxin 1 - Thioredoxin Reductase 1
Expression of thioredoxin (TXN/TRX-1) and TXNRD1 genes are both regulated via ARE
and Nrf2 at the transcriptional level (Kim et al. 2001, Sakurai et al. 2005). TRXs are
ubiquitously expressed and highly conserved antioxidant enzymes that reduces oxidized
thiol  groups in  proteins.  The TXN family  contains  two known members;  cytoplasmic  and
nuclear TRX-1, and mitochondrial TRX-2. Both forms have a critical -Cys-Gly-Pro-Cys- site,
which is essential for reduction-oxidation function (Cys32 and Cys35 in TRX-1). During the
reduction of proteins, thioredoxin itself oxidizes. TXNRD1 is an enzyme that reduces TRXs
in an NAD(P)H-dependent reaction (Holmgren, Lu 2010). Cytosolic TRX-1 regulates cell
death and survival signaling pathways by controlling interactions of TRX-binding proteins
(Saitoh et al. 1998). Under oxidative stress, TRX-1 translocates to the nucleus where it
modulates the DNA-binding activity of transcription factors (Altschmied, Haendeler 2009).
In healthy vessels, TRX-1 is mainly expressed in SMCs but in vessels containing
atherosclerotic lesions TRX-1 is also expressed in the endothelium and in macrophages
(Okuda et al. 2001). Thioredoxin is an important inhibitor of apoptosis signaling kinase 1
(ASK-1, Figure 9B). TRX-1 binds to the N-terminus of ASK-1 both in vitro and in vivo, thus
inhibiting its downstream effects (Saitoh et al. 1998). If the activity of TRX-1 is inhibited,
TNF- phosphorylates ASK-1, leading to the activation of downstream p38 and Jun-
terminal kinase (JNK) (Ichijo et al. 1997). Downstream kinases mediate the expression of
adhesion and inflammatory genes, such as VCAM1. TRX-1 also has a role in signaling
pathways mediated by physiological concentrations of ROS in endothelial cells. One
mechanism  is  the  modification  of  Cys69  by .NO that leads to increased TRX-1 redox-
regulatory activity, reduction of intracellular ROS, and inhibition of apoptosis (Haendeler
et al. 2004, Haendeler et al. 2002). The activity of TRX-1 is increased in shear stress.
Increased S-nitrosylation of TRX-1 and decreased S-nitrosylation of TXNIP might be the
main mechanisms (Hoffmann, Dimmeler & Haendeler 2003, Yamawaki et al. 2005).
Recently, it has been proposed that mitochondrial TRX-2 also plays a role in cardiovascular
diseases because its function is similar to that of TRX-1 (Dai et al. 2009).
2.5.3.4.2 Thioredoxin Interacting Protein
TXNIP (also termed vitamin D-upregulated protein 1, VDUP1) inhibits TRX-1 activity in a
redox-dependent manner by binding reduced TRX-1 but not oxidized TRX-1 (Nishiyama et
al. 1999). The oxidation status of TXNIP is also important. TXNIP has two important
cysteines; Cys63 and Cys247 that mediate TRX-1 binding through disulfide complex
formation (Patwari et al. 2006). In the endothelium, shear stress down-regulates TXNIP
expression to support the cytoprotective effects of TRX-1. In contrast, in low or turbulent
flow  TXNIP  expression  is  induced  and  this  leads  to  the  formation  of  TRX-1-TXNIP
complexes. This results in a release of ASK-1 from TRX-1 and the activation of the ASK-1 -
TNF- mediated pro-inflammatory pathway (Yamawaki et al. 2005). In SMCs, .NO reduces
TXNIP  expression  and  enhances  TRX-1  activity  without  affecting  the  TXR-1-TXNIP
complex formation, supporting the protective role of .NO in the vascular wall (Schulze et al.
2006). .NO also induces protein S-nitrosylation via transcriptional repression of TXNIP, thus
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releasing TRX-1, which then acts in the denitrosylation pathway, protecting cells against
nitrosative stress (Forrester et al. 2009). The TRX-1-TXNIP-complex also has a role in redox-
dependent regulation of vascular endothelial growth factor receptor-2 signaling that
supports survival in endothelial cells (World, Spindel & Berk 2011).
The  transcriptional  regulation  of  TXNIP  is  mainly  studied  in  pancreatic  and
cancer cell lines, where it is regulated via multiple transcription factors and stimuli. Only a
few studies demonstrate the transcriptional regulation of TXNIP in vascular cells. In human
aortic endothelial cells TXNIP expression is induced in glucose mediated manner by the
forkhead box O1 transcription factor, which leads to increased ROS production (Li et al.
2009). In macrophages, TXNIP is transcriptionally regulated via an AP-1 site. The binding
of  c-Jun  and  c-Fos  to  the  TXNIP  AP-1  element  is  inhibited  in  the  presence  of  PPAR or
PPAR agonist GW647. However, even though the regulatory region of TXNIP contains a
putative PPAR binding site it does not bind it directly (Billiet et al. 2008).
Figure 9. The TRX-1-TXNIP system. A, When TXNIP is expressed it binds to TRX-1, leading to
the  activation  of the ASK-1 pathway and increased expression of adhesion molecules and
proinflammatory genes. B, During repression of TXNIP, TRX-1 binds ASK-1 to inhibit its activity
and decrease inflammation. Modified from (Harrison 2005).
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3 Aims of the study
The aim of this thesis research was to explore the activation mechanisms of Nrf2 by agents
relevant to cardiovascular diseases, profiling new target genes and finding regulatory
mechanisms in human and mouse vascular endothelial cells.
I To investigate whether oxPLs evoke nuclear translocation of Nrf2 and
activation of target gene expression in human endothelial cells and mouse
carotid arteries, and to identify the specific phospholipids that are responsible
for Nrf2 activation.
II To elucidate the role of OA-NO2 as an Nrf2 activating agent and explore OA-
NO2 inducible, Nrf2-dependent and -independent genes to through a genome-
wide approach.
III To investigate whether transcription factor BACH1 is a novel Nrf2 target gene
and identify the genomic region responsible for the Nrf2 mediated effect.
IV To demonstrate the role of Nrf2 in down-regulation of TXNIP and explore the
mechanisms by which Nrf2 plays a role in negative gene regulation.
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4 Materials and methods
4.1 NRF2 ACTIVATING AGENTS AND CELL CULTURE (I-IV)
Phospholipids  were  purchased  from  Avanti  Polar  Lipids  or  Sigma  or  synthesized  as
described (Watson et al. 1999). OA-NO2 was synthesized as previously described
(Woodcock S R et al. 2006, studies II, III, IV). SFN (Sigma-Aldrich, studies III, IV), and tBHQ
(Sigma-Aldrich, study III) are commercially available. Human umbilical vein endothelial
cells  (HUVECs,  studies  I-IV)  were  isolated  from  umbilical  cords  obtained  from  the
maternity ward of Kuopio University Hospital, by the approval of the Kuopio University
Hospital Ethics Committee, and cultivated as previously described (Levonen et al. 2004).
Human embryonic kidney 293T cells (HEK293T, studies III, IV) were purchased from
ATCC. HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (Sigma-
Aldrich), supplemented with 10% (v/v) fetal bovine serum (HyClone) and 1%
penicillin/streptomycin (Invitrogen-Gibco).
4.2 CLONING OF PLASMIDS (I-IV)
For luciferase reporter assays, wild type or mutated AREs of NQO1 or BACH1 were cloned
into  the  pGL3-promoter  vector  (studies  I,  II,  and  IV)  or  pGL4-promoter  vector  (study  III,
Promega) containing the minimal thymidine kinase promoter (Turunen et al. 2007). For
study  IV,  the  full  length  TXNIP  promoter  region  was  PCR  amplified  from  DNA  isolated
from  human  blood  cells  and  cloned  into  the  pGL3-backbone.  Specific  oligonucleotides
containing the required restriction sites were acquired from TAG Copenhagen.
Complementary oligonucleotides were annealed and ligated into their respective restriction
sites of the pGL3- or pGL4-promoter vector (Promega) and verified by sequencing. Details
of the primers and cloning are described in studies I-IV.
4.3 CLONING OF ADENOVIRUSES (III, IV)
The cloning of AdNrf2 has been previously described (Levonen et al. 2007). The pAd-Keap1
was cloned by excising the BamHI-XhoI fragment containing the human Keap1 cDNA from
pCDNA3 and ligating the fragment into pAdCMV. The pAd-Keap1 was then used to
generate the recombinant adenoviruses using standard techniques (Kozarsky, Wilson 1993).
AdNrf2 was used in studies III and IV, AdKeap1 in study IV.
4.4 SIRNA TRANSFECTIONS (I-IV)
Small interfering RNA (siRNA) oligonucleotides targeting Nrf2 (studies I-IV), HSF1 (study
II),  Nrf1  (study  III),  and  a  non-specific  RNA  control  were  obtained  from  Invitrogen.
HUVECs were transfected with 50 nM siRNA oligonucleotides using Oligofectamine
(Invitrogen).
4.5 RNA ISOLATION AND QUANTITATIVE REAL-TIME PCR (I-IV)
Messenger RNA was extracted with TRI-reagent (Invitrogen) and 0.5-1 μg of total-RNA
was used for the cDNA synthesis using random hexamer primers (Promega) and ReverAid
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M-MuLV reverse transcriptase (Fermentas Life Sciences). The relative expression levels of
target mRNA were measured according to the manufacturer’s protocol by quantitative RT-
PCR (StepOnePlusTM Real-Time PCR systems, Applied Biosystems), using specific Assays-
on-Demand (Applied Biosystems). The expression levels were normalized to the level of
ribosomal RNA or 2-microglobulin (Applied Biosystems). The target mixes used are
presented in Table 1.
Table 1. Analyzed genes and used assays for quantitative RT-PCR
Gene Assay ID Study
Nuclear factor-E2 Related Factor 2, NFE2L2 Hs00232352_1 I, II, III, IV
Nuclear factor-E2 Related Factor 1, NFE2L1 Hs00231457_m1 III
Heme Oxygenese-1, HO-1 Hs00157965_m1 I, II
NAD(P)H; quinone oxidoreductase 1, NQO1 Hs00168547_m1 I, II, III
Glutamate-cysteine ligase modifier subunit, GCLM Hs00157694_m1 I, II
BACH1 transcript variant 1 and 2 Hs00230917_m1 III
BACH1 transcript variant 1 Custom assay III
BACH1 transcript variant 3 Hs01110003_s1 III
BACH1 all transcript variants Hs00895421_m1 III
2-microglobulin, B2M Hs00187842_m1 II, III
Heat shock 70 kDa protein 1A, HSPA1A Hs00359147_s1 II
DNAJ (Hsp40) homolog A4, DNAJA4 Hs00388055_m1 II
Heat shock 22 kDa protein 8, HSPB8 Hs00205056_m1 II
Heat shock 70 kDa protein 6, HSPA6 Hs00275682_m1 II
Heat shock factor 1, HSF1 Hs00232134_m1 II
Thioredoxin Interacting protein 1, TXNIP Hs00197750_m1 IV
Thioredoxin, TXN Hs00828652_m1 IV
Thioredoxin reductase 1, TXNRD1 Hs00182418_m1 IV
Heme Oxygenase-1, Ho-1 Mm00516004_m1 I
NAD(P)H; quinone oxidoreductase 1, Nqo1 Mm00500821_m1 I
Glutamate-cysteine ligase modifier subunit, Gclm Mm00514996_m1 I
4.6 WESTERN BLOTTING (I, II, IV)
Cells  were  lysed  and  the  total  protein  concentration  was  measured  with  a  BCA-assay
(Pierce).  Ten  to  20  μg  of  protein  were  used  for  electrophoresis.  The  proteins  were
transferred to a nitrocellulose membrane, blocked, and incubated with primary antibodies.
The primary antibodies used were rabbit polyclonal anti-Nrf2 (sc-722, Santa Cruz
Biotechnologies,  studies I  and II),  rabbit polyclonal anti-HO-1 (Stressgen, studies I  and II),
rabbit  monoclonal  anti-GCLM  (a  gift  from  Dr.  Terrance  Kavanagh,  University  of
Washington, Seattle, WA, studies I and II), mouse monoclonal anti-NQO1 (Clones A180
and B771, gifts from Dr. David Ross, University of Colorado, Denver, CO, studies I and II),
rabbit polyclonal -actin (Cell Signaling, studies I, II and IV), rabbit polyclonal anti-Lamin
B1 (Abcam,  studies  I  and II),  mouse monoclonal  anti-HSP70/72  (Assay Designs,  study II),
rabbit polyclonal anti-HSF1 (Cell Signaling, study II), and rabbit polyclonal anti-VDUP1 (C-
terminal, 403700, Invitrogen). Blots were visualized using HRP-conjugated secondary
antibodies and Supersignal™ chemiluminescence substrate (Pierce, Rockford, IL).
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4.7 LUCIFERASE REPORTER GENE ASSAY (I-IV)
Activation of the ARE by Nrf2 activating agents or Nrf2 co-transfection was measured
using the luciferase Reporter Assay (Promega) with HUVECs (studies I and II) or HEK293T
cells  (studies  III  and  IV).  In  studies  I  and  II,  HUVECs  were  transfected  with  an  empty
pGL3-promoter vector, NQO1-ARE or NQO1-AREmut luciferase reporter plasmids as in
((Levonen et al. 2004)). Sixteen hours after transfection, the cells were treated with 50 μg/ml
of oxPAPC (study I) or increasing concentrations of OA-NO2 (study II supplement). After
16 h, the cells were collected and analyzed as described. In study III, HEK293T cells were
transfected with wild type or mutated NQO1-, BACH1-ARE1 or BACH1-ARE2 and 16 h
after transfection treated with SFN, tBHQ or OA-NO2 for 24 h. In addition, HEK293T cells
were co-transfected with BACH1-ARE1 or NQO1-ARE and Nrf2 with or without Keap1. In
study  IV,  HEK293T  cells  were  transfected  with  the  TXNIP  promoter  construct  with  or
without Nrf2 and Keap1.
4.8 CHROMATIN IMMUNOPECIPITATION (CHIP, I-IV)
ChIP  was  performed  as  described  in  study  I  with  some  modifications.  HUVECs  or
HEK293T cells were treated with Nrf2 activating agents for 2 to 3 h. DNA-protein
complexes were cross-linked with 1% formaldehyde and stopped with 0.125 mol/l glycine.
Nuclear pellets were extracted and chromatin was sonicated to 200 to 1000 bp fragments by
a Bioruptor UCD-200 (Diagenode). Cellular debris was removed by centrifugation and
samples were prepared for immunoprecipitation. The following antibodies were used in
immunoprecipitations; anti-Nrf2 (sc-722, Santa Cruz Biotechnologies, studies I, II, III), anti-
Maf F/G/K (sc-22831, Santa Cruz Biotechnologies, study III), anti-HSF1 (SPA901, Stressgene,
study II), anti-BACH1 (sc-14700, Santa Cruz Biotechnologies, study III) or nonspecific IgG
(anti-rabbit IgG, Upstate Biotechnology, all studies). Immunocomplexes were collected and
washed, reverse cross-linked and then DNA was extracted for PCRs. Immunoprecipitated
chromatin DNA was then used as a template for reverse trasnscriptase-PCR or quantitative
real-time PCR. ChIP protocols, PCR primers and amplification protocols are described in
detail in their respective studies.
4.9 APPLICATION OF OXPAPC TO THE CAROTID ARTERIES AND
IMMUNOHISTOCHEMISTRY (I)
Nrf2-/- mice were a kind gift from Dr. Masayuki Yamamoto, University of Tsukuba, Japan,
and the mouse creation approach has been previously described (Chan et al. 1996, Itoh et al.
1997). Wild type C57Bl/6 were originally obtained from the Jackson laboratory. Mice were
housed in groups and maintained in controlled conditions in the National Laboratory
Animal Center in Kuopio. Experiments were approved by the Experimental Animal
Committee of the University of Kuopio and the National Experimental Animal Board. The
application of oxPAPC, dissolved in pluronic gel, to mouse carotid arteries was performed
as previously described (Furnkranz et al. 2005). Both genders of wild type or Nrf2-/- mice (6
mo of age) were used for the study. The animals were anesthetized using ketamine
(Ketalar, Pfizer), xylazin (Rompun Vet, Bayer) and Lidocaine (Lidocain Orion Pharma). The
left carotid artery was exposed through a midline cervical incision and 60 μl of 30%
pluronic  gel  with  or  without  50  μg/ml  oxPAPC  was  applied  on  the  carotid  artery.  The
wound was closed, animals were sacrificed with carbon dioxide 6 h after the surgery and
carotid arteries were collected for mRNA analysis with quantitative PCR, or 24 h after for
immunohistochemistry. For immunohistochemistry, carotid arteries were cast in paraffin
and stained against rabbit polyclonal anti-HO-1 (Stressgene) and anti-NQO1 (Abcam), the
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avidin-biotin-horseradish peroxidase system (Vector laboratories) and DAB-plus kit
(Zymed laboratories) were used for signal detection.
4.10 MICROARRAY ANALYSIS (II)
For microarray analysis, HUVECs from three separate donors were pooled and transfected
with 50 nM Nrf2 or non-specific control siRNA using Oligofectamine (Invitrogen). Twenty-
four hours after transfection, cells were treated with methanol (vehicle), 3 μM OA, or 3 μM
OA-NO2 for  8  h.  The  mRNA  was  extracted  with  TRI-reagent  (Sigma)  according  to  the
manufacturer’s protocol and probes for the expression analysis were made according the
Affymetrix protocol. Complementary RNA was hybridized to Human Genome U133 Plus
2.0 GeneChips (Affymetrix) and chips were stained, washed (Affymetrix Fluidics Station
400) and scanned (Affymetrix GeneChip Scanner 3000) according to the manufacturer’s
protocol. Microarray data were extracted from scanned images by using MAS 5.1 software
(Affymetrix) and GeneChip Operating Software (GCOS, Affymetrix) was used to generate
CEL files. The details of data handling and statistical analysis are discussed in study II.
4.11 ELECTROMOBILITY SHIFT ASSAY (III)
For the electromobility shift  assay (EMSA), the DNA binding region of Nrf2 (amino acids
327-605 (Wild, Moinova & Mulcahy 1999)) and MafG cDNA (German Research Center for
Genome Research, Germany) were amplified by PCR and cloned into the pcDNA3 vector
with a Kozac sequence. Nrf2 and MafG proteins were generated by coupled in vitro
transcription/translation using a TNT Quick Coupled Transcription/Translation kit as
recommended by the supplier (Promega, Madison, WI, USA). The proteins were incubated
with  [32P]-labeled double-stranded oligonucleotides containing one copy of the respective
response elements. Protein-DNA complexes were resolved by electrophoresis and
quantified on an FLA-3000 reader (Fuji, Tokyo, Japan) using ScienceLab99 software (Fuji).
Further details are described in study III.
4.12 STATISTICAL ANALYSIS (I-IV)
Statistical analyses were performed with GraphPad Prism Software (GraphPad Software,
Inc.). Statistical significance was evaluated by unpaired t-test or one-way ANOVA using
Bonferroni’s post hoc comparisons. Results are expressed as mean±SEM and differences
depicted as *p<0.05, **p<0.01, ***p<0.001.
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5 Results
5.1 OXPAPC AND OA-NO2 ACTIVATES NRF2 DEPENDENT TARGET GENE
EXPRESSION (I-II)
Nrf2 has been shown to be activated by multiple agents. Herein we studied the effect of
two agents relevant to cardiovascular disease, oxPAPC and OA-NO2,  on the  activation of
Nrf2  and the  induction of  target  genes  HO-1,  GCLM, and NQO1.  Both oxPAPC and OA-
NO2 induce  Nrf2  target  genes  in  concentration  and  time  dependent  ways  in  HUVECs
(studies I and II). The nuclear accumulation of Nrf2 increased upon oxPAPC treatment
time-dependently (Figure 10A) and the translocation is reduced when siRNA against Nrf2
was used (Figure 11A).
Figure 10. OxPAPC induce nuclear accumulation of Nrf2, and the expression of Nrf2 target genes
Nrf2-dependently. A, Nuclear and cytoplasmic Nrf2 from HUVECs treated with 50 μg/ml oxPAPC
0 to 4 h detected by Western blotting.  Lamin B1 was used as a nuclear protein control.  B-E,
HUVECs were transfected with 50 nM siControl or siNrf2 and cells were treated with 50 μg/ml
oxPAPC 24 h after transduction for 8 h. The expression of Nrf2 (B), HO-1 (C), GCLM (D), and
NQO1  (E)  were  detected  by  quantitative  RT-PCR.  The  expression  was  normalized  to  the
ribosomal  RNA,  and  presented  as  fold  change  compared  to  untreated  siControl.  Values  are
presented as meanSEM, (n=3), *p<0.05 vs. untreated siControl, #p<0.05 vs. oxPAPC treated
siControl. Modified from study I.
OxPAPC and OA-NO2 induce the activation of Nrf2 and the increase in target gene
expression was reduced with siNrf2 (Figures 10B-E, and Figures 11B-E). Induction of
GCLM (Figure 10D, and Figure 11D) and NQO1 (Figure 10E, and Figure 11E) mRNA and
protein expression (studies I and II) was blocked when siNrf2 was used. HO-1 (Figure 10C,
and Figure 11C) is not blocked as effectively as other Nrf2 targets with siNrf2, suggesting
that there are redundant pathways taking part in the induction.
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Figure 11. OA-NO2 induce nuclear accumulation of Nrf2, and the expression of Nrf2 target genes
Nrf2-dependently. HUVECs  were  transfected  with  50  nM  siControl  or  siNrf2  and  cells  were
treated with 3 μM OA-NO2 24 h after transduction for 8 h. A, Nuclear and cytoplasmic Nrf2 were
detected  by  Western  blotting.  Lamin  B1  was  used  as  a  nuclear  protein  control.  B-E,  The
expression of  Nrf2 (B),  HO-1 (C),  GCLM (D),  and NQO1 (E) was detected by quantitative RT-
PCR,  normalized  to  the  ribosomal  RNA,  and  presented  as  fold  change  compared  to  the
untreated siControl. Values are presented as meanSEM, (n=3), *p<0.05 vs. relative siControl.
Modified from study II.
The activation of ARE-dependent expression was studied by the luciferase reporter assay.
Both oxPAPC and OA-NO2 activate NQO1-ARE and the activation was inhibited by point
mutation of the ARE (Figures 12A, and B). Binding of Nrf2 to NQO1 and HO-1 AREs was
verified by ChIP (Figures 12C, and D).
Figure 12. OxPAPC and nitrolipids activate AREs and induce the binding of  Nrf2 to the ARE of
HO-1 and NQO1. A-B, For the luciferase assay, HUVECs were transfected with empty pGL3 -
promoter vector as a control, or vector containing wild type or mutated NQO1-ARE. Twenty-four
hours after transfection, cells were treated with 50 mg/ml oxPAPC, 2.5 or 5 μM OA, or 2.5 or 5
μM OA-NO2 for 16 h. Luciferase activity was normalized to total protein or -galactosidase and
presented  relative  to  empty  vector  control.  Values  are  presented  as  meanSEM, (n=3-4), B,
*p<0.05 vs.  relative control.  C-D, HUVECs were treated with 50 μg/ml oxPAPC for  3 h,  3 μM
LNO2 or OA-NO2 for 4 h. Binding of Nrf2 to the ARE of the HO-1 or NQO1 was analyzed by ChIP.
Rabbit IgG and H2O were used as an immunoprecipitation control, and a nonspecific exon area
from the HO-1  gene  was  used  as  a  negative  PCR  control.  Results  are  representative  of  3
independent experiments. Modified from studies I and II.
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5.2 IDENTIFICATION OF CRITICAL STRUCTURAL CHARACTERISTICS OF
OXPAPC MEDIATING NRF2 ACTIVATION (I)
Next the structural requirements of oxPAPC for Nrf2 activation were studied. First the role
of the polar head group in the sn-3 position was examined. HUVECs were treated with
native or oxPLs having palmitoyl and arachidonoyl in positions sn-1 and sn-2 respectively,
but phosphocholine in the sn-3 position was replaced with phosphatidylglycerol,
phosphatidic acid, phosphatidylethanolamine, or phosphatidylserine.
The  mRNA  expression  of  NQO1  and  GCLM  was  increased  by  all  studied
oxPLs suggesting that the polar head group in the sn-3 position does not play a significant
role in the activation (Figure 13A). Native PLs did not induce the expression. During PAPC
oxidation  three  oxPLs  differing  from  the  sn-2  position  are  formed;  PGPC,  POVPC  and
PEIPC (isoprostane-PC). When HUVECs were treated with: PGPC, POVPC, PEIPC (Figure
13B) or LysoPC (1-palmitoyl-2-hydroxyl-sn-3-glycero-phosphocholine, study I) that
contains a hydroxyl group in the sn-2 position, the expression of GCLM and NQO1 were
induced only by PEIPC. For further verification of the importance of the isoprostane group,
cells were treated with native or oxidized palmitoyl-linoleoyl-phosphatidylcholine (PLPC)
that cannot form prostanoid structures. Nevertheless, oxPLPC activated target gene
expression, indicating that the isoprostane group is not the only important structure for
activation (Fig 13C). GCLM was also induced by PAPC hydroperoxide (PAPCOOH) but
not by the reduced hydroxide form (PAPCOH, Figure 13D).
Figure 13. The induction of Nrf2 target genes by different classes of phospholipids. A, HUVECs
were treated with 130 μmol/l native or oxidized PAPC, phosphatidylglycerol (PAPG),
phosphatidic acid (PAPA), phosphatidylethanolamine (PAPE), or phosphatidylserine (PAPS) for 6
h. B, HUVECs were treated with 130 μmol/l oxPAPC or isoprostane-PC for 6 h. C, HUVECs were
treated  with  130  μmol/l  native  or  oxidized  PLPC.  D,  HUVECs  were  treated  with  130  μmol/l
PAPCOOH  or  PAPCOH  for  6  h.  The  expression  of  GCLM  and  NQO1  mRNA  was  analyzed  with
quantitative  RT-PCR  and  normalized  to  B2M.  The  expression  was  presented  as  fold  change
compared to the untreated siControl. Values are presented as meanSEM, (n=3), *p<0.05 vs.
siControl. Modified from study I.
Next  the  role  of  the  electrophilic  groups  in  oxPAPC  was  examined.  By  reducing
electrophilic  groups  of  oxPAPC  with  sodium  borohydride,  or  incubating  with  small
molecular weight thiols N-acetylcysteine or GSH, the expression of GCLM, NQO1 and HO-
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1 was investigated (study I). In summary, these results show that oxPLs with an oxidized
group in the sn-2 position (an isoprostane or hydroperoxide residue) are capable of
activating Nrf2 mediated gene expression. In addition, the electrophilic character of
oxPAPC and its active components have a significant role in the activation.
5.3 OXPAPC INDUCES NRF2 TARGET GENES IN VIVO (I)
To explore the effect of oxPAPC on Nrf2 dependent target gene induction in vivo,
surgically exposed carotid arteries of wild type and Nrf2-/- mice were covered with pluronic
gel with or without 50 μg oxPAPC. The expression of HO-1, GCLM and NQO1 mRNA was
significantly induced by oxPAPC in wild type mice arteries and Nrf2 deficiency inhibited
the induction (Figures 14A, B, and C). Similar effects were seen in immunohistochemical
analysis where samples were stained against HO-1 or NQO1. Again oxPAPC treatment
increased protein levels in wild type mice whereas the induction was prevented in Nrf2-/-
arteries  (Figures  14D,  and  E).  To  summarize,  Nrf2  is  activated  and  induces  target  gene
expression by oxPAPC both in vitro and in vivo.
Figure 14. OxPAPC induces the expression of target genes in murine carotid arteries. The
carotid  arteries  of  wt  or  Nrf2-/-(KO)  mice  were  surgically  exposed  and  covered  with  30%
pluronic gel with or without 50 μg oxPAPC. A-C, Animals were sacrificed after 6 h treatment and
mRNA expressions of HO-1 (A), GCLM (B), and NQO1 (C) were measured with quantitative RT-
PCR. The expression was normalized to ribosomal RNA, and presented as fold change compared
to the untreated wt control. Values are presented as meanSEM, (n=5-11), *p<0.05 vs. relative
control. D and E, Animals were sacrificed after 24 h, and the protein expression of HO-1 (D) and
NQO1 (E) was measured by immunostaining. The arrowhead indicates HO-1 positivity. Original
magnification x400, scale bars=50 μm, L=lumen, M=media, A=adventitia. Modified from
study I.
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5.4 NRF2 DEPENDENT AND INDEPENDENT EFFECTS OF OA-NO2 ON THE
MRNA EXPRESSION OF HUVECS (II)
The effects of OA-NO2 on the expression profile of HUVECs and the identification of Nrf2-
dependent and -independent target genes responsive to OA-NO2 were  studied  by  a
microarray analysis.  HUVECs were  transfected with nonspecific  siRNA or  siRNA against
Nrf2 for 24 h and treated with OA-NO2 or OA for 8 h. Untreated transfected cells were used
as a control. Genome-wide transcriptional profiling comparing untreated and OA treated
cells did not shown any significant difference revealing that the effects of OA-NO2 are
specific. OA-NO2 treatment leads to the up-regulation of 363 and down-regulation of 103
genes. SiNrf2 specifically down-regulated 150 and up-regulated 34 genes. The number of
genes that were regulated by both OA-NO2 and siNrf2 were 43, where 31 genes were up-
regulated  by  OA-NO2 and down-regulated by siNrf2. Most of those genes were known
Nrf2 targets. These results indicate that the majority of the effects of OA-NO2 are mediated
by  other  mechanisms  and  transcription  factors  other  than  Nrf2.  Using  the  geneset
enrichment  analysis,  it  was  shown  that  one  of  the  major  pathways  activated  by  OA-NO2
was the HSR. Multiple genes known to be involved in HSR were significantly up-regulated
after OA-NO2 treatment. The expression of the selected HSR targets was verified by RNA
and protein expression analysis, siRNA experiments using siRNA against HSF1 and
binding of HSF1 to the heat shock response element of the target genes after OA-NO2
treatment (study II).
5.5 BACH1 IS AN NRF2 INDUCIBLE GENE (III)
Previous microarray studies with Nrf2 over-expressing adenovirus (Jyrkkänen et al. 2006)
and our previous study (II) suggest that BACH1 might be an Nrf2 inducible gene. Kaspar
and Jaiswal have also shown that BACH1 is induced by tBHQ treatment in human and
mice hepatic cells (Kaspar, Jaiswal 2010). Thus we hypothesized that BACH1 is a new Nrf2
target gene. HUVECs were transduced with Nrf2 over-expressing adenovirus with MOI 10
to 100. The expression of BACH1 transcript variants was induced by AdNrf2 and by
treating HUVECs with Nrf2 activating agents; SFN, tBHQ or OA-NO2 (Figures 15A, and B,
study III). The induction was inhibited by using actinomycin D, showing that the induction
is  regulated at  the  transcriptional  level  (study III).  Nrf2  dependency of  BACH1 induction
was studied by siNrf2 that inhibits SFN activated induction of BACH1 expression (Figure
15C), indicating that Nrf2 mediates BACH1 induction by SFN.
Figure 15. Nrf2 induces mRNA expression of human BACH1. A,  HUVECs were transduced with
Nrf2 over-expressing adenovirus using MOI 10 to 100 for 48 h. B, HUVECs were treated with 0
to  10  μM  SFN  for  6  h.  C,  HUVECs  were  transfected  with  siRNA  against  Nrf1,  Nrf2  or  control
siRNA for  48 h and treated with 10 μM SFN for  6 h.  The expression of  BACH1 was measured
with quantitative RT-PCR and normalized to B2M. Values are presented as meanSEM, (n=3). A
and B; vs. control, C; untreated vs. treated cells, *p<0.05. Modified from study III.
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The promoter of the BACH1 gene was studied with in silico analysis using the Genomatix
software. Two putative core ARE sequences (TGAC/GnnnGC, (Erickson et al. 2002)) were
found in the BACH1 gene. The elements were located on the forward strand 1270 (BACH1-
ARE2) and reverse strand 1411 (BACH1-ARE1) downstream from the TSS of transcript
variant 2 (study III).
The functionality of the elements was tested by EMSA and luciferase reporter
assays. In EMSA analysis, Nrf2 and small Mafs form a strong complex with BACH1-ARE1,
whereas BACH1-ARE2 does not show any binding (study III). Binding of Nrf2 to BACH1-
ARE1 was decreased with a specific NQO1-ARE but not with a nonspecific NF-B element,
confirming the specificity of binding. In the luciferase assay, BACH1-ARE1 was strongly
activated by Nrf2 activating agents (Figure 16A).
The  activation  of  BACH1-ARE1  was  further  studied  by  co-transfection  with
Nrf2 and Keap1, demonstrating Nrf2 mediated activation. NQO1-ARE was used as a
control in the experiments.  Binding of Nrf2 was further confirmed by ChIP. Results show
that Nrf2 binds to the BACH1 ARE after SFN treatment (Figure 16B). Taken together, these
results indicate that the inducible expression of BACH1 is regulated by Nrf2 via an intronic
ARE.
Figure  16.  The  binding  of  Nrf2  to  the  AREs  of  BACH1  or  NQO1. A,  For  the  luciferase  assay,
HEK293T  cells  were  transfected  with  empty  pGL-promoter  vector  as  a  control,  or  vectors
containing wild type or mutated BACH1 or NQO1 AREs. Twenty-four hours after transfection,
cells were treated with 10 μM SFN, 30 μM tBHQ, or 5 μM OA-NO2 for 16 h. Luciferase activity
was  normalized  to -galactosidase  and  presented  relative  to  an  empty  vector  control.  B,
HEK293T cells were treated with 10 μM SFN for 2 h and ChIP was performed using an antibody
against  Nrf2.  Quantitative RT-PCR against  BACH1, or  NQO1 ARE or against  actin as a specific
control  was  performed.  Binding  is  presented  as  %  of  input  values  from  three  independent
experiments. Values are presented as meanSEM,  (n=3),  *p<0.05  vs.  control  treatment.
Modified from study III.
5.6 NRF2 NEGATIVELY REGULATES THE EXPRESSION OF TXNIP (IV)
The thioredoxin system is one of the most important reductive pathways in mammalian
cells.  TXNIP  inhibits  the  thioredoxin  system  leading  to  the  activation  of  inflammatory
pathways and increased ROS production. It is known that TXNIP is down-regulated by
laminar shear stress, which also activates Nrf2. TXNIP expression is down-regulated by
adenoviral Nrf2 over-expression. TXNIP expression is also decreased in OA-NO2 treated
siControl cells by 1.8 fold (study II). We therefore first examined the effect of adenoviral
Nrf2 over-expression on TXNIP mRNA. The TXNIP mRNA expression was reduced by 86.6
± 3.7% with AdNrf2 MOI 50 and 91.7 ± 1.5% with MOI 100 (Figure 17A) comparing to
control virus. The highest MOI used also reduced TXNIP protein levels (study IV). The
effect of the Nrf2 inhibitor, Keap1, was also tested by transducing HUVECs with AdKeap1.
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Keap1 over-expression increased TXNIP mRNA expression approximately 1.5 fold.
Treatment with Nrf2 activating agent SFN, lead to the reduction of both TXNIP mRNA and
protein  expression dose-  and time-dependently  (study IV).  Transfection of  HUVECs with
specific siRNA against Nrf2 induced TXNIP expression 1.9 fold (Figure 17B). However,
SFN treatment significantly repressed TXNIP expression also when siNrf2 was used,
suggesting an Nrf2-independent component is involved in its effect (Figure 17B). We also
examined mRNA expression of  TXNRD1 and TXN as  these  are  important  components  of
the TXN system. TXNRD1 is tightly regulated by the Nrf2-ARE and its expression is clearly
Nrf2 dependent, as shown by Nrf2 over-expression, SFN treatment or siNrf2 (study IV). In
contrast, TXN expression was not affected by these treatments.
Figure  17.  TXNIP  expression  and  promoter  activity  is  reduced  by  Nrf2. A,  HUVECs  were
transduced  with  Nrf2  over-expressing  adenovirus  using  MOI  10  to  100  for  48  h.  B,  HUVECs
were transfected with siRNA against Nrf2 or control siRNA for 48 h and treated with 10 μM SFN
for  6  h.  The  expression  of  TXNIP  was  measured  with  quantitative  RT-PCR  and  normalized  to
B2M. Values are presented as meanSEM, (n=3), *p<0.05. C, For the luciferase assay, HUVECs
were transfected with the construct containing 3224 nucleotides upstream from the TXNIP TSS,
or  empty  pGL3  -promoter  vector  as  a  control  with  Nrf2-  and  Keap1-expressing  plasmids.
Twenty-four  hours  after  transfection,  cells  were  treated  with  10  μM  SFN  for  16  h.  Luciferase
activity was normalized to -galactosidase and presented relative to the empty vector control.
Modified from study IV.
To study the effect of Nrf2 on the TXNIP transcription, a 3224 nucleotides regulatory region
upstream of the TXNIP TSS was cloned into a pGL3-vector and the promoter activity was
studied with the luciferase reporter assay. The HEK293T cells were transfected with the
pGL3-TXNIP-promoter construct along with Nrf2- and Keap1-expressing plasmids. Nrf2
reduced the activity of the TXNIP-promoter (Figure 17C). Keap1 alone has no effect and it
was not able to inhibit the repressive activity of Nrf2. The SFN treatment did not increase
the repressive effect of Nrf2 (Figure 17C). However, in HUVECs transfected with the pGL3-
TXNIP-promoter  without  Nrf2  co-transfection,  SFN  repressed  the  promoter  activity  of
TXNIP (study IV).
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In silico analysis of the TXNIP regulatory region revealed two putative AREs (Figure 18A)
3544 and 2453 nucleotides upstream from the TXNIP TSS. The data, from the Encyclopedia
of DNA Elements project (ENCODE), reveals the presence of markers for active promoter
(H3K4Me3) and active enhancer regions (H3K4Me1 and H2K27A) as open chromatin in
that area (Figure 18B). The Blat sequences display the location of putative AREs. Only the
proximal element was included in the promoter construct used, necessitating the validation
of the distal element.
Figure 18. Putative AREs of theTXNIP gene and the ENCODE data set displays the TXNIP region.
A, The sequences of putative TXNIP AREs are located at -3544 and -2453 from the TSS, aligned
to  the  ARE  consensus  and  NQO1  ARE  sequences  (Wasserman,  Fahl  1997).  B,  ENCODE  data
from the TXNIP region displaying putative AREs (Blat sequences), active promoter (H3K4Me3)
and enhancer regions (H3K4Me1 and H2K27A), and TF ChIPseq data. Modified from study IV.
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6 Discussion
6.1 ACTIVATION OF NRF2 BY AGENTS RELEVANT TO CARDIOVASCULAR
DISEASES
Lipids and inflammation play a central role in atherogenesis. Different classes of modified
lipids are formed in plasma and in the cells of the vascular wall during atherogenesis.
OxPAPC is produced during oxidation of LDL in cell membranes and has been shown to be
localized in human atherosclerotic lesions and plays a role in all stages of atherogenesis
(Gargalovic et al. 2006a, Bochkov et al. 2010). Endogenous OA-NO2 is found in cardiac
mitochondria, cardiac tissue and plasma, and its production is increased during
inflammation (Rudolph et al. 2010b, Nadtochiy et al. 2009, Tsikas et al. 2009). In this thesis,
it  is  shown  that  both  oxPAPC  and  OA-NO2 activate nuclear localization of Nrf2 and the
target gene expression in human endothelial cells and murine carotid arteries (studies I and
II).
Nrf2 activation is mediated via Keap1 modifications. OA-NO2 seems  to  bind
the Cys273 and Cys288 of Keap1, leading to a conformational change in the Keap1-Nrf2-
CUL3 complex (Kansanen et al. 2011, Tsujita et al. 2011). In contrast, the exact activation
mechanism of Nrf2 by oxPAPC is not known. OxPAPC that contains esterified
cyclopentenone isoprostane, PEIPC (Watson et al. 1999), which is important in the
activation of adaptive branches of the UPR (Oskolkova et al. 2008). In this thesis it was
shown that isoprostane phospholipids is a favorable Nrf2 activator. PEIPC contains an
isoprostane group that is highly similar to the cyclopentenone group of 15d-PGJ2 that
modifies Keap1 cysteines (Levonen et al. 2004). OxPLs and specifically PEIPC are capable of
modifying intracellular proteins (Gugiu et al. 2008, Jung et al. 2008). Therefore, it can be
suggested that PEIPC induced Nrf2 activation is mediated via modification of Keap1 Cys
residues. Otherwise, oxPAPC increases Nox mediated production of O2.- and this has been
proposed as one of the mechanisms for Nrf2 activation (Li et al. 2007, Rouhanizadeh et al.
2005). Nrf2 dependent activation of oxidative stress induced growth inhibitor 1 is
dependent on Nox mediated ROS production and induction is inhibited by using Nox
inhibitors. As discussed in study I, we examined the effect of Nox4 silencing on the
expression of Nrf2 target genes using siRNA or apocynin treatment without seeing any
effect, supporting the hypothesis that oxPAPC directly actives the Keap1-Nrf2 pathway.
NO2-FAs activate many anti-inflammatory signaling pathways in endothelial
cells. Since NO2-FAs can act on multiple signaling pathways, we wanted to identify Nrf2-
dependent and -independent OA-NO2 targets by microarray analysis. Several genes up-
regulated  by  OA-NO2 treatment and down-regulated with siNrf2 were previously
identified Nrf2 targets, thus confirming that the approach was feasible. However, the
number of genes was quite small and for methodological reasons some Nrf2 targets may
have been excluded. Most of the OA-NO2 induced genes were not Nrf2 dependent. Using
gene enrichment analysis, the predominant pathway was HSR. HSR is activated by e.g.
elevated temperatures  and by electrophilic  compounds.  In  endothelial  cells,  expression of
HSPs such as HSP70 has been shown to inhibit inflammation via inhibition of NF-B and to
display cytoprotective effects via protection against H2O2 (Westerheide, Morimoto 2005,
Ran et al. 2004, Gill et al. 1998). Thus the activation of HSR supports the anti-inflammatory
feature of OA-NO2.
The activation of cytoprotective signaling pathways is a physiological response
to the generation of ROS and ageing. These pathways are the key defense against harmful
effects of ROS. In addition to their independent effects, these protective pathways have a
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certain degree of cross-talk between each other. Signaling by Keap1-Nrf2 pathway and HSR
is mediated by different transcription factors, but both are activated by electrophilic lipids,
such as  OA-NO2 (study II) and 15d-PGJ2 (Zingarelli et al. 2007). Genome-wide analysis of
Nrf2 and HSF1 target genes indicates that these do not overlap, supporting the notion that
responses are largely distinct (study II, (Trinklein et al. 2004)). However, there is evidence
that Nrf2 and HSF1 share common signaling proteins, which modulate their activation and
DNA binding (Niture, Jaiswal 2010, Kaitsuka, Tomizawa & Matsushita 2011). It has been
demonstrated in hepatoma cells that the Keap1-CUL3-complex is disrupted by HSP90,
leading to Nrf2 activation upon heat shock (Niture, Jaiswal 2010). Our studies (study II,
supplement) do not support this observation since heat shock does not activate expression
of the Nrf2 target gene HO-1 in HUVECs. As discussed with phosphorylation, the effects
are cell type and target gene dependent (Kensler, Wakabayashi & Biswal 2007), suggesting
that the effect of heat shock leading to Nrf2 activation might also be cell type or target gene
specific.
 In  summary,  oxPLs  and  NO-FAs  are  Nrf2  activator  molecules  present  in  the
vasculature during stress conditions. They activate several signaling pathways, mediating
both anti- and pro-atherogenic effects. Protective signaling pathways cross-talk with each
other to fine-tune the signaling effects.
6.2 REGULATION OF NOVEL NRF2 TARGET GENES
Nrf2 is demonstrated to be a transactivator that regulates gene expression via an ARE. The
number of experimentally confirmed Nrf2 target genes is limited and new targets are yet to
be found. The expression of BACH1 mRNA induced by electrophiles was Nrf2 dependent
and  mediated  by  an  intronic  ARE.  Nrf2  has  no  effect  on  the  basal  expression  of  BACH1,
verified  by  the  siRNA  experiment  (study  III).  This  indicates  that  the  basal  expression  is
supported by other transcription factors. The ChIP results indicate that the same amount of
small Mafs is bound to the BACH1 ARE in basal conditions and upon SFN treatment. The
basal expression of the TXN-1 gene is regulated by an NF-E2-small Maf complex and heme
induced expression is regulated by an Nrf2-small Maf complex via an ARE (Kim et al.
2001). It could be suggested that the basal expression of human BACH1 might be mediated
by the ARE, but by a transcription factor other than Nrf2. The role of Nrf1 in compensating
for Nrf2 deficiency through partially shared targets was researched in study III. However,
the use of siRNA against Nrf1 had no effect on BACH1 expression. Furthermore, BACH1
itself does not regulate its own activity via an ARE, as confirmed by ChIP. It is possible that
small Mafs act as homodimers to repress the basal expression, similar to what has been
demonstrated with the MafG gene (Kataoka et al. 1995b). BACH1 is also regulated post-
translationally by miRNAs, which provides another layer of regulation to its expression
(Hou et al. 2010, Yin et al. 2008).
Nrf2  is  a  highly  inducible  transcription  factor  and  it  drives  target  gene
expression effectively. It has recently been suggested that hyperactivated Nrf2 can mediate
liver disease (Komatsu et al. 2010). The mechanisms by which Nrf2 activation is turned off
are not known. Our results suggest that Nrf2 negatively regulates its own activity via
BACH1.  BACH1 competes  with  Nrf2  for  the  same binding sites  and by inducing BACH1
expression, Nrf2 negatively regulates its own target genes. This is particularly true with
HO-1 as the role of BACH1 in its expression is firmly established. However, the battery of
genes regulated by both Nrf2 and BACH1 is unclear. Recently ChIP combined with a high-
throughput sequencing technique was used for identifying targets of either Nrf2 or BACH1
(Warnatz et al. 2011, Malhotra et al. 2010). However, the overlap of genes regulated by both
of these two transcription factors at the same time has not yet been explored across the
genome.
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Herein, is demonstrated that TXNIP expression is down-regulated by Nrf2. In silico
analysis demonstrated that the regulatory area of TXNIP contains putative AREs, but
whether  these  are  functional  remains  to  be  investigated  (study  IV).  Nrf2  has  earlier  been
shown to down-regulate the expression of vascular inflammatory genes via the p38 kinase
(Zakkar et al. 2009, Chen et al. 2003). In human aortic endothelial cells, TXNIP is up-
regulated by forkhead box O1 transcription factor via p38 (Li et al. 2009). Therefore, it
remains to be clarified whether Nrf2 affects the TXNIP expression via the same mechanism.
However, as demonstrated in this thesis, SFN also has an Nrf2-independent repressive role
in TXNIP regulation. We have also seen that other electrophilic Nrf2 activators, such as OA-
NO2,  functions  the  same way.  These  findings  suggest  that  the  down-regulation of  TXNIP
may be affected by cellular redox balance. That hypothesis is supported by Schulze et al,
who studied the role of TXNIP in SMC proliferation. The authors demonstrated that H2O2
treatment decreased TXNIP protein expression over short time points and the reduction
was inhibited with antioxidants (Schulze et al. 2002). In addition, it has been shown that the
oxidative status of TXNIP regulates its cellular localization (Saxena, Chen & Shalev 2010)
and its expression further induces ROS production (Junn et al. 2000). However, the role of
redox balance in transcriptional and translational regulation of TXNIP needs to be clarified
further. In macrophages, TXNIP is regulated via an AP-1 region by the transcription factors
c-Jun and c-Fos (Billiet et al. 2008). These factors are known to bind to the internal AP-1
within the ARE and they have a role in the regulation of ARE target genes. For example,
TXR-1 is regulated by these factors as well as by ARE binding factors such as Nrf2, in
different conditions (Kim et al. 2001). Also, it is known that Nrf2 and Jun proteins together
regulate TXR-1 expression via an ARE or the internal AP-1 element (Venugopal, Jaiswal
1998).
6.3 ROLE OF NRF2 IN VASCULAR DISEASES
Nrf2  has  been  reported  to  have  conflicting  roles  in  atherogenesis.  Via  induction  of
protective target genes, Nrf2 is potentially antiatherogenic. In the endothelium, Nrf2
maintains cellular homeostasis and the antiatherogenic role of Nrf2 has been demonstrated
in vivo (Zakkar et al. 2009). This is also supported by studies within this thesis, since Nrf2 is
demonstrated to be activated by endogenously presented lipids, activation of protective
genes, and inhibition of inflammation in endothelial cells. In macrophages, Nrf2 has
important protective features via Nrf2 target genes and at the same time it potentiates foam
cell formation via increased expression of CD36 (Ishii et al. 2004). However, as a main
function of macrophages is to scavenge xenobiotics in cells, it should be considered that
(via  induction  of  CD36)  Nrf2  may  protect  cells  from  modified  lipids  and  upon
atherogenesis these pious mechanisms become reversed. The role of Nrf2 in atherogenesis
has been studied in ApoE-/- mice.  ApoE-/- mouse  provide  a  commonly  used  model  of
atherosclerosis, where the deficiency of ApoE causes an increase in plasma cholesterol that
leads to the development of advanced lesions, even for mice on a low fat diet (Veniant et al.
2008). In an ApoE-/- background, Nrf2 increases lesion size (Barajas et al. 2011, Sussan et al.
2008). Barajas et al noted that the lesion size in male mice correlated with total and non-
HDL plasma cholesterols, which were decreased in Nrf2-/- males (Barajas et al. 2011).
Increased CD36 expression was demonstrated in Nrf2 expressing mice in both studies,
which has been postulated to increase foam cell formation in an Nrf2-dependent fashion.
However, Barajas et al discussed that there are multiple mechanisms by which Nrf2
accelerates atherogenesis. They noticed that Nrf2 has multiple effects on lipid metabolism
that are partially sex dependent. The severe atherosclerotic model together with a high-fat-
diet may confuse the progression of the atherogenesis. It would therefore be valuable to
study  the  role  of  Nrf2  in  a  less  severe  model,  such  as  in  LDL-receptor  deficient  mice
expressing ApoB100 only. The ApoB100 only/LDLR-/- model mimics the lipid profile of
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human disease better than ApoE-/- (Veniant et al. 1998). Our preliminary data with ApoB100
only/LDLR-/- mice on a normal diet suggests that Nrf2 is antiatherogenic (Ruotsalainen A-K
et al. 2011). A study with ApoE-/- -BACH1-/- mice shows that the induction of Nrf2 inducible
HO-1, due to BACH1 deficiency, inhibits lesion formation (Watari et al. 2008). However,
HO-1 is expressed in advanced atherosclerotic lesions and induces thickening of the fibrous
cap and SMC accumulation, but on the other hand it has been shown to decrease necrosis
and inhibit plaque rupture (Cheng et al. 2009). To conclude, it seems that Nrf2 has both pro-
and anti-inflammatory features. It has been demonstrated that a polymorphism of the Nrf2
gene associates with oxidative stress induced lung diseases (Marzec et al. 2007) and Nrf2
mutations  are  common  in  many  cancer  types,  contributing  to  poorer  prognosis  of  the
disease (Taguchi, Motohashi & Yamamoto 2011). Whether these mutations are common in
atherosclerosis is not known, but they may explain the dual role of Nrf2 in atherogenesis. In
summary, Nrf2 plays a protective role in the endothelium but in the later phase of the
disease, constitutive Nrf2 activation in macrophages promotes their survival and
atherogenesis. Therefore, further studies are needed to explore the role of Nrf2 in different
cell types and phases of atherogenesis.
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7 Conclusions
I OxPAPC  induced  the  expression  of  target  genes  HO-1,  NQO1  and  GCLM  in
human endothelial cells and in murine carotid arteries in an Nrf2 dependent
manner. The characterization of lipid species that are critical for gene activation
showed that the oxidation of the sn-2 group, isoprostane, hydroxyl- or
electrophilic groups all play a role.
II Nrf2 is activated and its target genes are induced by OA-NO2. Most of the OA-
NO2 induced genes are Nrf2 independent, the heat shock response being one of
the main activated pathways.
III The repressive transcription factor BACH1 is a novel Nrf2 target gene. Nrf2
regulates inducible expression of BACH1 via an intronic ARE. This may serve
as a novel mechanism by which Nrf2 regulates its own activity by negative
feedback.
IV Nrf2 downregulates the expression of TXNIP in endothelial cells and can thus
act as a negative regulator of gene expression.
To conclude, Nrf2 is activated by endogenous agents relevant to cardiovascular diseases
and it has a multifunctional role in gene regulation in endothelial cells. The role of Nrf2 in
atherogenesis is controversial, but the results shown in this thesis support the action of Nrf2
as an endothelial protector. However, future studies are needed to establish the role of Nrf2
in other vascular cell types and at different stages of atherogenesis. According to the
knowledge available, it can be hypothesized that endothelium specific activation of Nrf2
may prevent endothelial dysfunction and the progression of atherogenesis.
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Increased production of reactive 
oxygen species (ROS) disrupts 
vascular homeostasis leading to 
the development of endothelial 
dysfunction and atherosclerosis. 
Transcription factor Nrf2 protects 
cells against ROS via regulation of 
antioxidant and cytoprotective genes. 
In this thesis, the mechanisms by 
which endogenous molecules activate 
Nrf2 in the vascular endothelium 
are described. In addition, novel 
mechanisms that inhibit the Nrf2 
activity and the role of Nrf2 as a factor 
decreasing the vascular inflammation 
are suggested.
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